0001656472-25-000014 | 10-K | XBRL Viewer

Print Document

Investments - Schedule of Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024
Schedule of Equity Method Investments [Line Items]
Equity method investments, net	$ 0	$ 19,488
Share of income from equity method investments	2,365	1,583	$ 3,114
Equity Method Investment, Summarized Financial Information [Abstract]
Current assets	936,113	933,306
Current liabilities	49,700	41,399
Income Statement [Abstract]
Revenue	117,615	87,241	86,749
Gross profit	25,198	11,909	15,436
Net income	40,022	(74,553)	(168,734)
Equity Method Investments
Equity Method Investment, Summarized Financial Information [Abstract]
Current assets	0	19,600	21,158
Non-current assets	0	99,227	104,227
Current liabilities	0	9,707	5,593
Non-current liabilities	0	64,814	73,779
Income Statement [Abstract]
Revenue	22,191	40,604	39,110
Gross profit	10,529	21,565	24,379
Net income	$ 3,514	$ 3,051	6,569
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%	50.00%
Equity method investments, net	$ 0	$ 19,488		$ 53,542
Share of income from equity method investments	$ 2,365	$ 1,583	$ 3,114

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Related Party Transactions

The Company made the following purchases of cannabis products from Cronos GrowCo:


	Year ended December 31,
	2024(i)		2023		2022
Cronos GrowCo – purchases	$	16,952	$	21,335	$	18,144

(i)2024 activity presented above represents purchases from Cronos GrowCo for the first six months of the year.

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2024

Risks and Uncertainties [Abstract]

Schedule of Fair Value of Assets on Recurring Basis

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	As of December 31, 2024
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	858,805	$	—	$	—	$	858,805

Other investments(i)	2,813		—		—		2,813
Derivative liabilities	—		—		40		40


	As of December 31, 2023
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	669,291	$	—	$	—	$	669,291
Short-term investments	192,237		—		—		192,237
Other investments(i)	9,601		—		—		9,601
Derivative liabilities	—		—		102		102

(i)As of December 31, 2024 and December 31, 2023, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 5 “Investments” for additional information.

Schedule of Fair Value of Assets on Nonrecurring Basis

The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

As of December 31, 2024

Level 1

Level 2

Level 3

Total

Other investments(i)

—


	As of December 31, 2023
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	25,650	25,650

(i)Other investments measured at fair value on a non-recurring basis relate to our investment in PharmaCann. See Note 5 “Investments”.

Investments

12 Months Ended

Dec. 31, 2024

Equity Method Investments and Joint Ventures [Abstract]

Investments

(a)Variable interest entities and investments in equity method investments, net

CLS

The Company holds a variable interest in Cannasoul Lab Services Ltd. (“CLS”). CLS is a wholly owned subsidiary of Cannasoul Analytics Ltd., incorporated with the purpose of establishing a commercial cannabis analytical testing laboratory located on the premises of Cronos Israel (the “Cannasoul Collaboration”). Cronos Israel agreed to advance up to ILS 8,297 ($2,664) by a non-recourse loan (the “Cannasoul Collaboration Loan”) to CLS over a period of two years from April 1, 2020 for the capital and operating expenditures of the laboratory. The loan bears interest at 3.5% annually. Cronos Israel will receive 70% of the profits of the laboratory until such time as it has recovered 150% of the amounts advanced to CLS, after which time it will receive 50% of the laboratory profits. As a result, the Company is exposed to economic variability from CLS’s performance. The Company does not consolidate CLS as it does not have the power to direct the activities that most significantly impact the entity’s economic performance; thus, the Company is not considered the primary beneficiary of the entity. The carrying amount of the non-recourse loan is recorded under loans receivable and the full loan amount, ILS 8,297, represents the Company’s maximum potential exposure to losses through the Cannasoul Collaboration. See Note 6 “Loans Receivable, net” for further information regarding loans receivable.

Cronos GrowCo

As a result of the Cronos GrowCo Transaction, the existing equity method investment in Cronos GrowCo was remeasured at its fair value on July 1, 2024. For the year ended December 31, 2024, we recorded a gain of $32,469 on the consolidated statements of net income (loss) and comprehensive income (loss) from remeasuring our equity method investment in Cronos GrowCo. See Note 2 “Business Combination” for further information regarding the Cronos GrowCo Transaction.

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2024		2023

Cronos GrowCo(i)	50%	$	—	$	19,488

(i)The Company obtained control of Cronos GrowCo on July 1, 2024, and, as a result, the investment in Cronos GrowCo is now accounted for as an intercompany transaction and eliminated upon consolidation from the business combination date onwards.

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2024		2023		2022

Cronos GrowCo(i)	2,365		1,583		3,114

	$	2,365	$	1,583	$	3,114

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2024		2023		2022
Current assets	$	—	$	19,600	$	21,158
Non-current assets	—		99,227		104,227
Current liabilities	—		9,707		5,593
Non-current liabilities	—		64,814		73,779


	Year ended December 31,
	2024		2023		2022
Revenue	$	22,191	$	40,604	$	39,110
Gross profit	10,529		21,565		24,379
Net income	3,514		3,051		6,569

The following is a summary of the maximum exposure to loss from the Company’s investments in equity method investments as of December 31, 2023:


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss
Cronos GrowCo	50%	$	44,306	$	19,488


Balance as of December 31, 2023		$	44,306	$	19,488

The Company’s maximum exposure to loss is equal to the carrying amount of the investment.

(b)Other investments

Other investments consist of investments in common shares and options of two companies in the cannabis industry.

PharmaCann Option

On June 14, 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The option exercise will be based upon various factors, including the status of U.S. federal cannabis legalization, as well as regulatory approvals, including in the states where PharmaCann operates that may be required upon exercise. The Company has deemed its influence in PharmaCann to be non-significant. The PharmaCann Option is classified as an investment in an equity security without a readily determinable fair value. The Company measures the PharmaCann Option at cost less accumulated impairment charges, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The PharmaCann Option is reported as Other investments on the consolidated balance sheet for the periods ended December 31, 2024 and 2023.

On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of December 31, 2024 and 2023, based on updated information provided by PharmaCann in the fourth quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 5.8% and 5.9%, respectively. Under the terms of the Company’s investment in PharmaCann, the Company’s rights to nominate an observer or a director to the PharmaCann board of directors could be lost if the Company’s ownership drops below 6% on a fully diluted basis and it sells or transfer all or any portion of the option (subject to certain exceptions). The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option.

During the first, third and fourth quarters of 2022, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the income approach and the market approach. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, cash flow projections, and the expectation of federal rescheduling and individual state legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of these analyses, the Company recorded non-cash impairment charges of $11,238, $28,972 and $21,182 in the first, third and fourth quarters of 2022, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the consolidated statements of net income (loss) and comprehensive income (loss).

During the fourth quarter of 2023, the Company identified adverse forecast changes in the financial performance of PharmaCann as an indicator of impairment related to the PharmaCann Option and conducted an analysis comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the income approach and the market approach. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, cash flow projections, and the expectation of federal rescheduling and individual state legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of this analysis, the Company recorded a non-cash impairment charge of $23,350 in the fourth quarter of 2023 as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2023.

During the first and second quarters of 2024, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using the market approach. Under the market approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of these analyses, the Company recorded non-cash impairment charges of $12,734 and $12,916 in the first and second quarters of 2024, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2024. As a result of the impairment charge recorded in the second quarter of 2024, the net book value of the PharmaCann Option was reduced to zero.

Vitura (formerly known as Cronos Australia)

The Company accounts for its investment in Vitura using the fair value method of accounting, with unrealized holding gains and losses included in net income (loss) on the consolidated statements of net income (loss) and comprehensive income (loss). The Company recorded a loss on revaluation of other investments of $6,206 for the year ended December 31, 2024, and a loss on revaluation of other investments of $12,096 for the year ended December 31, 2023, included in the loss on revaluation of financial instruments on the statements of net income (loss) and comprehensive income (loss). The Company’s investment in Vitura was $2,813 and $9,601 as of December 31, 2024 and 2023, respectively, and is included in other investments on the consolidated balance sheets. On February 12, 2025, Vitura issued 74,814,757 shares. This issuance diluted the Company’s ownership to approximately 8.4%.

The following table summarizes the Company’s other investments activity:


	As of December 31, 2023		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2024
PharmaCann	$	25,650	$	—	$	(25,650)	$	—	$	—
Vitura	9,601		(6,206)		—		(582)		2,813
	$	35,251	$	(6,206)	$	(25,650)	$	(582)	$	2,813


	As of December 31, 2022		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2023
PharmaCann	$	49,000	$	—	$	(23,350)	$	—	$	25,650
Vitura	21,993		(12,096)		—		(296)		9,601
	$	70,993	$	(12,096)	$	(23,350)	$	(296)	$	35,251

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 858,805	$ 669,291
Short-term investments	0	192,237
Accounts receivable, net	15,462	13,984
Interest receivable	8,690	10,012
Other receivables	5,000	6,341
Current portion of loans receivable, net	618	5,541
Inventory, net	33,149	30,495
Prepaids and other current assets	6,277	5,405
Held-for-sale assets	8,112	0
Total current assets	936,113	933,306
Equity method investments, net	0	19,488
Other investments	2,813	35,251
Non-current portion of loans receivable, net	15,526	69,036
Property, plant and equipment, net	133,189	59,468
Right-of-use assets	1,390	1,356
Goodwill	63,453	1,057
Intangible assets, net	11,257	21,078
Deferred tax assets	2,571	226
Total assets	1,166,312	1,140,266
Current liabilities
Accounts payable	16,973	12,130
Income taxes payable	9	64
Accrued liabilities	31,653	27,736
Current portion of lease obligation	1,025	994
Derivative liabilities	40	102
Current portion due to non-controlling interests	0	373
Total current liabilities	49,700	41,399
Non-current portion due to non-controlling interests	1,073	1,003
Non-current portion of lease obligation	993	1,559
Deferred tax liabilities	3,564	181
Total liabilities	55,330	44,142
Shareholders’ equity
Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2024 and 2023: unlimited; shares outstanding as of December 31, 2024 and 2023: 382,530,780 and 381,298,853, respectively)	669,879	662,174
Retained earnings	457,709	416,719
Accumulated other comprehensive income (loss)	(63,525)	20,678
Total equity attributable to shareholders of Cronos Group	1,064,063	1,099,571
Non-controlling interests	46,919	(3,447)
Total shareholders’ equity	1,110,982	1,096,124
Total liabilities and shareholders’ equity	$ 1,166,312	$ 1,140,266

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net income (loss)	$ 40,022	$ (74,553)	$ (168,734)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation	8,700	8,769	15,115
Depreciation and amortization	9,336	8,110	13,122
Impairment loss on long-lived assets	16,350	3,571	3,493
Impairment loss on other investments	25,650	23,350	61,392
Loss (income) from investments	3,841	10,513	(17,853)
Loss (gain) on revaluation of derivative liabilities	(49)	85	(14,060)
Changes in expected credit losses on long-term financial assets	1,032	(1,528)	(662)
Revaluation of equity method investment	(32,469)	0	0
Revaluation of loan receivable	(11,804)	0	0
Loss on held-for-sale assets	11,202	0	0
Inventory step-up recorded to cost of sales	5,284	0	0
Foreign currency transaction (gain) loss	(57,859)	7,324	2,286
Other non-cash operating activities, net	(82)	(2,008)	1,294
Changes in operating assets and liabilities:
Accounts receivable, net	(917)	9,206	(2,711)
Interest receivable	(3,656)	(14,344)	(6,985)
Other receivables	2,059	(1,449)	1,148
Prepaids and other current assets	(512)	1,437	996
Inventory, net	7,417	7,399	(7,217)
Accounts payable	(7,449)	(773)	(863)
Income taxes payable	(93)	(33,104)	34,212
Accrued liabilities	2,840	5,160	(2,921)
Net cash provided by (used in) operating activities	18,843	(42,835)	(88,948)
Investing activities
Proceeds from short-term investments	185,817	532,838	268,870
Purchase of short-term investments	0	(608,247)	(271,378)
Cash acquired in business combination	5,993	0	0
Dividends received from equity method investee	0	1,297	0
Dividend proceeds	0	345	384
Advances on loans receivable	(8,759)	0	0
Proceeds from loans receivable	5,252	16,831	5,246
Purchase of property, plant and equipment, net of disposals	(12,411)	(2,505)	(3,451)
Purchase of intangible assets, net of disposals	(743)	(918)	(1,581)
Other investing activities	0	860	68
Net cash provided by (used in) investing activities	175,149	(59,499)	(1,842)
Financing activities
Withholding taxes paid on equity awards	(1,231)	(1,030)	(2,829)
Other financing activities, net	0	0	(68)
Net cash used in financing activities	(1,231)	(1,030)	(2,897)
Effect of foreign currency translation on cash and cash equivalents	(3,247)	8,011	(28,642)
Net change in cash and cash equivalents	189,514	(95,353)	(122,329)
Cash and cash equivalents, beginning of period	669,291	764,644	886,973
Cash and cash equivalents, end of period	858,805	669,291	764,644
Supplementary cash flow information:
Interest paid	0	0	0
Interest received	48,399	36,501	15,548
Taxes paid	$ 647	$ 33,013	$ 177

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Consolidated Entities

The Company consolidates the financial results of the following entities, which the Company controls but does not wholly own:

Subsidiaries

Jurisdiction of incorporation

Incorporation date

Ownership interest (iii)

Cronos Growing Company Inc.(i)

Canada

June 14, 2018

50%

Cronos Israel G.S. Cultivation Ltd.(ii)

Israel

February 4, 2018

70%

Cronos Israel G.S. Manufacturing Ltd.(ii)

Israel

September 4, 2018

90%

Cronos Israel G.S. Store Ltd.(ii)

Israel

June 28, 2018

90%

Cronos Israel G.S. Pharmacy Ltd.(ii)

Israel

February 15, 2018

90%

(i)Cronos Growing Company Inc. is referred to as “Cronos GrowCo.”

(ii)These Israeli entities are collectively referred to as “Cronos Israel.”

(iii)“Ownership interest” is defined as the proportionate share of net income to which the Company is entitled; equity interest may differ from ownership interest as described herein.

Schedule of Property, Plant and Equipment, Useful Lives

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

7 to 10 years

Furniture and fixtures

5 years

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2024		2023
Cost
Land		$	6,389	$	2,764
Building and leasehold improvements		192,059		168,498
Machinery and equipment		36,741		21,322
Furniture and fixtures		2,687		3,385
Construction in progress		28,710		3,269
Less: accumulated depreciation		(29,798)		(30,707)
Less: accumulated impairment charges		(103,599)		(109,063)
Property, Plant and Equipment, net		$	133,189	$	59,468

The following table presents details of the property, plant and equipment acquired on July 1, 2024, as a result of the Cronos GrowCo Transaction by major category:


	Fair value at date of Cronos GrowCo Transaction
Land	$	4,557
Building and leasehold improvements	49,356
Machinery and equipment	21,603
Furniture and fixtures	580
Construction in progress	11,534
Total	$	87,630

Schedule of Intangible Assets Amortization Methods and Rates

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities
Know-how(ii)	Straight-line	10 years

(i) The preliminary licenses granted to Kibbutz Gan Shmuel (the Cronos Israel joint venture partner) by the Medical Cannabis Unit of the Israeli Ministry of Health in early 2017 (the “Israeli codes”) were transferred by non-controlling interests to Cronos Israel in exchange for equity interests in the Cronos Israel entities specified above.

(ii) Know-how was acquired as part of the Cronos GrowCo Transaction. See Note 2 “Business Combination” for further information.

Intangible assets, net are comprised of the following items:


		As of December 31, 2024
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,988		$	(4,646)		$	(72)		$	2,270
Health Canada licenses		7,810			(1,673)			(6,137)			—
Ginkgo exclusive licenses		26,139			(5,329)			(20,810)			—
Israeli codes(i)		281			(76)			—			205
Know-how(ii)		7,665			(383)			—			7,282
Total definite-lived intangible assets		48,883			(12,107)			(27,019)			9,757
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	113,025		$	(12,107)		$	(89,661)		$	11,257


		December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

(ii) Know-how was acquired as part of the Cronos GrowCo Transaction. See Note 2 “Business Combination” for more information. Amortization costs associated with the know-how intangible asset are recorded to cost of sales on the consolidated statements of net income (loss) and comprehensive income (loss).

Accumulated impairment charges on intangible assets, net consist of:


	As of December 31, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2024
Software	$	(78)	$	—	$	6	$	(72)
Health Canada licenses	(6,650)		—		513		(6,137)
Ginkgo exclusive licenses	(7,968)		(14,258)		1,416		(20,810)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(77,338)	$	(14,258)	$	1,935	$	(89,661)


	As of December 31, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of December 31, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:


	As of December 31,
	2024		2023
Accrued payroll and related expenses	$	10,324	$	8,970
Accrued professional fees	1,537		2,525
Accrued taxes	11,831		11,695
Other accrued expenses	7,961		4,546
Total accrued liabilities	$	31,653	$	27,736

Schedule of Revenue from External Customers by Products and Services

The following table presents the Company’s revenue by major product category for continuing operations:


	Year ended December 31,
	2024		2023		2022
Cannabis flower	$	87,912	$	62,070	$	63,593
Cannabis extracts	29,168		24,569		22,522
Other	535		602		634
Net revenue	$	117,615	$	87,241	$	86,749

Schedule of Revenue from External Customers by Geographic Areas

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

The following table presents the Company’s revenue by major product category for our single segment:


	Year ended December 31,
	2024		2023		2022
Cannabis flower	$	87,912	$	62,070	$	63,593
Cannabis extracts	29,168		24,569		22,522
Other	535		602		634
Net revenue	$	117,615	$	87,241	$	86,749

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

Property, Plant and Equipment, net - Schedule of Property, Plant & Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (29,798)	$ (30,707)
Less: accumulated impairment charges	(103,599)	(109,063)
Property, Plant and Equipment, net	133,189	59,468
Land
Property, Plant and Equipment [Line Items]
Cost	6,389	2,764
Building and leasehold improvements
Property, Plant and Equipment [Line Items]
Cost	192,059	168,498
Machinery and equipment
Property, Plant and Equipment [Line Items]
Cost	36,741	21,322
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Cost	2,687	3,385
Construction in progress
Property, Plant and Equipment [Line Items]
Cost	$ 28,710	$ 3,269

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a)Commitments R&D commitments On September 4, 2018, the Company announced an R&D partnership with Ginkgo to develop scalable and consistent production of a variety of certain common and lesser-known cannabinoids. As part of this partnership, Cronos agreed to issue up to 14,674,903 common shares of the Company (aggregate value of approximately $100,000 as of July 17, 2018 assuming all milestones are met, collectively the “Ginkgo Equity Milestones”) in tranches and $22,000 in cash subject to Ginkgo’s achievement of certain milestones and to fund certain R&D expenses, including foundry access fees. During the years ended December 31, 2022 and December 31, 2021, 4,157,888 shares and 2,934,980 shares, respectively, of the Company’s common stock were issued in conjunction with this partnership. No shares were issued for the year ended December 31, 2024 or December 31, 2023. Other commitments On February 18, 2019, the Company entered into an agreement with a wholly owned subsidiary of Altria (which agreement was subsequently amended and restated to substitute Altria Pinnacle as a party thereto), to receive strategic advisory and project management services from Altria Pinnacle (the “Services Agreement”). Pursuant to the Services Agreement, the Company will pay Altria Pinnacle a monthly fee equal to the product of 105% and the sum of: (i) all costs directly associated with the services incurred during the monthly period, and (ii) a reasonable and appropriate allocation of indirect costs incurred during the monthly period. The Company will also pay all third-party direct charges incurred during the monthly period in connection with the services, including any reasonable and documented costs, fees and expenses associated with obtaining any consent, license or permit. The Services Agreement will remain in effect until terminated by either party. See Note 17 “Related Party Transactions.” (b)Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its consolidated financial condition but could be material to its results of operations for any particular reporting period depending, in part, on its results for that period. (i)Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and former Chief Financial Officer. The court consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5, promulgated thereunder, against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenue and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. The defendants moved to dismiss on February 8, 2021. On November 17, 2023, the court entered an order granting the motion and dismissed the case with prejudice. On December 1, 2023, the shareholder plaintiffs sought reconsideration of the dismissal, requesting that the court instead dismiss the action without prejudice and permit the plaintiffs to seek leave to further amend the complaint. On December 3, 2024, the Court issued an opinion and order granting the plaintiffs’ motion for reconsideration, and on January 10, 2025, the plaintiffs filed a second amended class action complaint. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim named (i) the Company, (ii) its Chief Executive Officer, (iii) former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleged breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleged that certain of the Company’s prior public statements about revenue and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim did not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court. On April 11, 2023, the plaintiff filed a Fresh as Amended Statement of Claim, which reflected the dismissal of the defendants for which an appeal was not sought, the removal of the claims for oppression under the Ontario Business Corporations Act and common law misrepresentation, as well as shortening the proposed class period. On October 10, 2023, the Superior Court certified the action on behalf of a class of persons or entities who acquired shares in the secondary market, including on the TSX and Nasdaq, during the period from May 9, 2019 to March 30, 2020, other than certain excluded persons. (ii)Regulatory Settlements On October 24, 2022, the Company announced regulatory settlements as follows: SEC Settlement On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the restatements of the Company’s 2019 and 2021 interim financial statements (the “Restatements”). The Company agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposed of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount. The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years. OSC Settlement On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the Ontario Securities Commission (the “OSC”), resolving the Restatements. Pursuant to the terms of the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Ontario Securities Act to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. (iii)Litigation and regulatory inquiries relating to marketing, distribution, import and sale of products On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million. The Cronos Israel defendants moved to dismiss the action on August 13, 2023. The court granted the motion (and similar motions filed by other defendants) on May 16, 2024, dismissing the plaintiffs’ petition for class certification without prejudice and their individual claims with prejudice, and ordering the plaintiffs to pay ILS 10 thousand to each of the defendants for costs. On July 14, 2024, the plaintiffs appealed to the Supreme Court of Israel seeking to overturn both the dismissal of plaintiffs’ individual claims and the award of costs. The appeal is pending. On January 18, 2024, the Company was notified that the Trade Levies Commissioner of the Israel Ministry of Economy and Industry initiated a public investigation of alleged dumping of medical cannabis imports from Canada into Israel. On July 9, 2024, the Commissioner announced a preliminary determination proposing to impose an anti-dumping duty on Canadian licensed producers. Under the proposal, the Company would have been subject to a proposed duty of 369%. The Commissioner determined not to impose a provisional duty at that time pending the conclusion of the Ministry’s investigation. The Company responded to requests for information from the Ministry. On November 10, 2024, the Trade Levies Commissioner published final findings under which the Company would be subject to a proposed duty of 175%. A provisional duty is not being imposed at this time. The Commissioner’s findings are being evaluated by an ad hoc advisory committee, which is expected to make recommendations to the Ministers of Economy and Finance and the Finance Committee of the Knesset of whether to impose a duty. The Company cannot predict the outcome of the ad hoc committee’s review or the determinations of the Ministers of Economy or Finance, or the Finance Committee of the Knesset. On December 12, 2024, the Minister of Economy announced a conflict of interest and recused himself from the evaluation of whether to impose a duty. As of the date of this filing, no government minister has been substituted for the Minister of Economy. On July 25, 2024, a group of cannabis cultivators filed an administrative petition in the District Court of Jerusalem, Israel, against the Trade Levies Commissioner and certain Israeli and Canadian businesses. The administrative petition sought a court order requiring the Trade Levies Commissioner to impose a temporary duty on cannabis imported from Canada during the pendency of the investigation until the date on which a final determination is made by the Ministry of Economy whether to impose a duty. On September 9, 2024, the Company filed a motion to join the litigation; the court granted the Company’s motion on September 23, 2024. On February 6, 2025, the court dismissed the administrative petition. We expect litigation and regulatory proceedings relating to the marketing, distribution, import and sale of our products to increase.

Financial Instruments - Schedule of Fair Value of Assets on Nonrecurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 2,813	$ 35,251	$ 70,993
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	0	25,650
Level 1 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	0	0
Level 2 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	0	0
Level 3 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 0	$ 25,650

Business Combination - Schedule of Property Plant and Equipment Acquired (Details) - Cronos GrowCo - USD ($) $ in Thousands	Dec. 31, 2024	Jul. 01, 2024
Business Acquisition [Line Items]
Property, plant and equipment	$ 87,630	$ 87,630
Land
Business Acquisition [Line Items]
Property, plant and equipment		4,557
Building and leasehold improvements
Business Acquisition [Line Items]
Property, plant and equipment		49,356
Machinery and equipment
Business Acquisition [Line Items]
Property, plant and equipment		21,603
Furniture and fixtures
Business Acquisition [Line Items]
Property, plant and equipment		580
Construction in progress
Business Acquisition [Line Items]
Property, plant and equipment		$ 11,534

Share-based Compensation - Schedule of Deferred Share Units Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Weighted average grant date fair value
Granting and vesting of DSUs	$ 8,700	$ 8,756	$ 15,008
Deferred Share Units (DSUs)
Weighted average grant date fair value
Balance at beginning of period	1,092	674
Granting and vesting of DSUs	450	450
Liabilities settled	(359)
Gain (loss) on revaluation	(54)	(32)
Balance at end of period	$ 1,129	$ 1,092	$ 674
Number of DSUs
Balance at beginning of period (in shares)	521,679	265,732
Granting and vesting of DSUs (in shares)	193,965	255,947
Liabilities settled (in shares)	(155,383)
Balance at end of period (in shares)	560,261	521,679	265,732

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cannabis Purchases \| Related Party
Related Party Transaction [Line Items]
Purchases	$ 16,952	$ 21,335	$ 18,144

Derivative Liabilities - Narrative (Details) $ in Thousands	Mar. 08, 2019 warrant $ / shares shares	Dec. 31, 2024 shares	Dec. 31, 2022 USD ($)
Altria Group, Inc. \| Cronos Group, Inc.
Derivative [Line Items]
Ownership interest	45.00%	40.90%
Balance held (in shares) \| shares		156,573,537
Altria Investment
Derivative [Line Items]
Shares issued (in shares) \| shares	149,831,154
Altria Warrant
Derivative [Line Items]
Number of warrants issued \| warrant	1
Derivative liability \| $			$ 0
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Top-up Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Exercise price, volume-weighted average price, measurement period	10 days
Exercise price, volume-weighted average price, measurement period, days preceding exercise	10 days

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year amounts have been reclassified to conform to the current year presentation of our consolidated financial statements, which includes discontinued operations. These reclassifications had no effect on reported results of operations and ending shareholders’ equity.

Basis of consolidation

Basis of consolidationThe accompanying consolidated financial statements include the accounts of the Company, and all entities in which the Company has a controlling voting interest or is the primary beneficiary of a variable interest as of and for the reporting periods. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. If an entity is not deemed to be a VIE, the Company consolidates the entity if the Company has a controlling voting interest. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. Investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not have control, are accounted for under the equity method of accounting.

In the consolidated statements of net income (loss) and comprehensive (income) loss, net income (loss) and comprehensive income (loss) are attributed to the equity holders of the Company and to the non-controlling interests. Non-controlling interests in the equity of Cronos Israel and Cronos GrowCo are presented separately in the shareholders’ equity section of the consolidated balance sheets and consolidated statements of shareholders’ equity. All intercompany transactions and balances are eliminated upon consolidation.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include, among other things, allocation of consideration to acquired assets and liabilities in a business combination, valuation of derivative liabilities, expected credit losses on long-term financial assets, gain on revaluation of loans receivable, gain on revaluation of equity method investment, impairment losses on goodwill and indefinite-lived intangible

assets, impairment losses on long-lived assets, inventory write-downs, share-bared payments, valuation allowance on deferred income tax assets and uncertain tax liabilities. Actual results could differ from those estimates.

Cash and cash equivalents and short-term investments

Cash and cash equivalents are comprised of cash and highly liquid short-term investments that are readily convertible into known amounts of cash, generally with original maturities of three months or less. Cash and cash equivalents include amounts held in dollars, C$, and ILS and security deposits. Short-term investments consist of debt securities that (i) generally have original maturities of greater than three months and (ii) the Company has the ability to convert into cash within one year.

Short-term investments are classified as held-to-maturity and recorded at cost. Interest earned on short-term investments is recorded in other receivables on the consolidated balance sheets and interest income, net on the consolidated statements of net income (loss) and comprehensive income (loss). Cash inflows and outflows related to the purchase and maturity of short-term investments are classified as investing activities in the Company’s consolidated statements of cash flows.

Business combination

Effective July 1, 2024, the Company obtained majority control of the board of directors of Cronos GrowCo, a cannabis cultivation company. The business combination was accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805 Accounting for Business Combinations (the “Cronos GrowCo Transaction”). Prior to this date, the Company’s investment in Cronos GrowCo was accounted for as an investment under the equity method and loans receivable from Cronos GrowCo. The excess of the fair value of our existing equity method investment over the net assets acquired was recorded as goodwill. The results of operations of Cronos GrowCo have been included in the Company’s consolidated financial statements from the acquisition date. Transaction costs associated with the acquisition were $701 in the year ended December 31, 2024 and were expensed as incurred.

Inventory

Inventory is comprised of raw materials, finished goods and work-in-progress, such as pre-harvested cannabis plants, dried flower, by-products to be extracted, cannabis extracts and by-products, dry cannabis and cannabis extract containers, and boxes. In relation to cultivated cannabis, the Company capitalizes costs into inventory until the time of harvest which includes, but is not limited to, labor, utilities, nutrition and irrigation.

Inventory is stated at the lower of cost and net realizable value, determined using weighted average cost. Cost includes expenditures directly related to manufacturing and distribution of the products. Primary costs include consumables (insect control, fertilizers, soil), packaging, shipping, direct labor, contract manufacturer fees, overhead, supplies and small tools, and the depreciation of manufacturing equipment and production facilities determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, rent, utilities, security, and property taxes. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment to measure inventory at the lower of cost and net realizable value. Factors considered in the determination of net realizable value include slow-moving or non-marketable products.

Variable interest entities

A variable interest entity is an entity having either a total equity investment that is insufficient to finance its activities without additional subordinated financial support or equity investors at risk that lack the ability to control the entity’s activities. Variable interests are investments or other interests that will absorb portions of a VIE’s expected losses or receive portions of the VIE’s expected residual returns. The Company evaluates whether it is the primary beneficiary of each VIE it identifies on a periodic basis and considers the impact of any reconsideration events. The primary beneficiary is the party that has both the power to direct the activities that most significantly impact the VIE and holds a variable interest that could potentially be significant to the VIE. To make this determination, the Company considers both quantitative and qualitative factors regarding the nature, size and form of its involvement with the VIE. The Company consolidates a VIE when it is determined that it is the primary beneficiary of the VIE.

Equity method investments

The Company accounts for investments in companies over which it has the ability to exercise significant influence but does not hold a controlling financial interest using the equity method. Under the equity method, the Company records its proportionate share of income or loss in share of income (loss) from equity method investments within the consolidated statements of net income (loss) and comprehensive income (loss). Cash payments to equity method investees such as additional investments or expenses incurred on behalf of investees, as well as income earned and payments from equity method investees such as dividends and distributions are recorded as adjustments to investment balances. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized in one period cannot be reversed in subsequent periods.

Other investments

Other investments include common stock and options in third-party entities in which the Company’s influence is deemed non-significant. The Company holds other investments with and without readily determinable fair values. Other investments with readily determinable fair values are recorded using the fair value method of accounting as of period-end on the consolidated balance sheets. Other investments without readily determinable fair values are recorded using the cost method of accounting on the consolidated balance sheets. Other investments without readily determinable fair values are assessed for observable price changes and other than temporary impairment on a periodic basis. Changes in the reported value of other investments are reported in the consolidated statements of net income (loss) and comprehensive income (loss).

Property, plant & equipment

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

7 to 10 years

Furniture and fixtures

5 years

When assets are disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized. Maintenance and repairs are charged to expense as incurred. Significant expenditures, which increase productivity or extend the useful life of the asset, are capitalized.

Available for use is defined as the point at which the related property, plant and equipment is operational, including the possession of any requisite licenses. Depreciation commences at the point the assets are available for use.

Definite-lived intangible assets

Intangible assets are recorded at cost less any accumulated amortization and accumulated impairment losses. Intangible assets acquired through a business combination are measured at fair value at the acquisition date. The fair value of the know-how intangible asset that was acquired in the Cronos GrowCo Transaction was estimated using the income approach. Under the income approach, significant inputs used in the relief-from-royalty method include projected revenues, royalty rate, income tax rate and discount rate.

The Company capitalizes certain costs incurred in connection with its enterprise software, which include external direct costs of materials and services consumed in developing or obtaining internal-use software and payroll and payroll-related costs for employees who are directly associated with and who devote time to the development of the software for the function intended. All other costs are expensed as incurred.

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities
Know-how(ii)	Straight-line	10 years

(ii) Know-how was acquired as part of the Cronos GrowCo Transaction. See Note 2 “Business Combination” for further information.

Amortization begins when assets become available for use. The estimated useful life, amortization method, and rate are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Intangible assets originating from the strategic partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) are accounted for in accordance with the acquisition method of accounting. Equity interests issued in exchange for an asset are initially recognized and measured at the date of acquisition at fair value. We estimate fair value using the relief-from-royalty method and key assumptions include the discount rate and estimated life. Definite-lived intangible assets, including intangible assets originating from the Ginkgo Strategic Partnership, are subject to amortization and reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value has been reduced to less than its carrying amount.

Accrued liabilities

Accrued payroll and related expenses include salaries and wages, bonuses, and other related payroll expenses associated with the Company’s employees. Accrued professional fees include fees for legal expenses, litigation, consulting, marketing, and other related expenses. Accrued taxes include sales, excise and other taxes owed. Other accrued expenses include the fair value of deferred share units outstanding to directors and other general expenses.

Leases

The Company enters into leases in the normal course of business, primarily for the land-use rights, office and research premises, and equipment used in the production of its products. At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company performs an analysis over the classification of the lease agreement as either an operating lease or finance lease.

A right-of-use asset and the related lease obligation associated with the lease are recorded at the inception of the lease. The right-of-use asset’s recorded amount is based on the present value of future lease payments over the lease term at the commencement date plus any initial direct costs incurred. If the rate implicit in the lease is not readily determinable for the Company’s operating leases, an incremental borrowing rate is generally used based on information available at the lease commencement date to determine the present value of future lease payments. Subsequent changes to these lease payments due to rate updates are recorded as lease expense in the period incurred. Leases with a term of 12 months or less are not recorded on the balance sheet as a lease.

The right-of-use asset is subject to impairment testing whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does

not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company.

The Company’s lease agreements generally exclude non-lease components. As a result, non-lease components are accounted for separately for all classes of assets and expensed as incurred. In addition, the Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of net income (loss) and comprehensive income (loss).

Derivative liabilities

Derivative liabilitiesFor financial instruments classified as derivatives that are not designated as hedging instruments or do not qualify for hedge accounting, changes in fair value are recorded in the consolidated statements of net income (loss) and comprehensive income (loss) each period. The Company does not enter into or hold derivative financial instruments for trading or speculative purposes. Derivative liabilities are initially recognized at fair value at the date on which the derivative contract was entered into. Any attributable transaction costs are recognized in net income (loss) as incurred. Subsequent to initial recognition, derivative liabilities are measured at fair value at each reporting date until settlement with the re-measurement gain or loss being recognized immediately in net income (loss) and comprehensive income (loss).

Capital stock

Capital stock is presented at the fair value at the time of issuance of the shares issued. Costs related to the issuance of shares are reported in equity, net of tax, as a deduction from the issuance proceeds.

Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. The Company’s contracts with customers for the sale of dried flower, cannabis oil, cannabinoid-derived products and “hemp” (as defined in the U.S. Agricultural Improvement Act of 2018 “U.S. hemp”) derived products consist of a single performance obligation.

The Company has concluded that revenue from the sale of these products should be recognized at the point in time when control is transferred to the customer, depending on the specific contractual terms. The Company has determined that the most definitive demonstration that control has transferred to a customer is physical shipment or delivery, depending on the contractual shipping terms, except for consignment transactions. Consignment transactions are arrangements where the Company transfers product to a customer or third-party location but retains ownership and control of such product until it is used by the customer. Revenue for consignment arrangements is recognized upon the customer’s usage.

Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Net revenue before excise taxes from sale of goods, as presented in the consolidated statements of net income (loss) and comprehensive income (loss), represents revenue from the sale of goods less expected price discounts, allowances for customer returns and other forms of variable consideration. If the consideration in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the goods to the customer. The variable consideration is estimated using either the expected value or most likely amount method, based on the Company’s historical information, at contract inception. The Company’s payment terms vary by customer and product type.

The Company treats shipping and handling activities as a fulfillment cost, classified as cost of sales. Accordingly, the Company accrues all fulfillment costs related to the shipping and handling of consumer goods at the time of shipment.

Research and development

Research and development The Company has a research and development center in Canada that performs scientific research on the interaction of cannabinoids as well as strain development, growing conditions and extraction technology. In 2023, fermentation and production related research was performed to further strategic initiatives around rare cannabinoids. In addition, the Company has a collaboration and license agreement with Ginkgo (the “Ginkgo Collaboration Agreement”) to research, produce, and commercialize cultured cannabinoids. Technological feasibility is considered to be established once productivity targets or commercialization are achieved, at which point the exclusive license is recognized at cost less impairment charges. As of the acquisition date of each exclusive license, cost less impairment charges is equal to the fair value.

Advertising costs

Advertising costsAdvertising costs include costs to sell the Company’s products and are expensed as incurred through sales and marketing expenses in the consolidated statements of net income (loss) and comprehensive income (loss).

Share-based compensation

Share-based awards consists of equity-settled share-based awards such as stock options and restricted share units (“RSUs”) that are issued to eligible employees, non-executive directors, and non-employees. Cash-settled deferred share units (“DSUs”) that are issued to non-executive directors under the DSU Plan are recorded in accrued liabilities with the fair value adjustment recorded in other income.

Equity instruments granted are initially measured at fair value on the grant date. The fair value of stock options is determined using the Black-Scholes option pricing model. The fair value of RSUs and DSUs are determined using the market price of the Company’s common shares. Compensation expense related to options and RSUs is recognized on a straight-line basis in the consolidated statements of net income (loss) and comprehensive income (loss) over the vesting period for employees, and over the contractual term for non-employees. The fair value of the payout of cash-settled DSUs is determined at each reporting date based on the fair value of the Company’s common shares at the reporting date and is recorded within other liabilities. The related costs for all equity-settled share-based awards are reflected in additional paid-in capital until the awards are settled or exercised. Upon settlement or exercise, shares are issued and the amount previously reflected in additional paid-in capital is, along with any proceeds paid upon settlement or exercise, credited to a combination of share capital and additional paid-in capital. Forfeitures of share-based compensation awards are accounted for as reductions to share-based compensation and additional paid-in capital as they occur.

Impairment of long-lived assets

The Company reviews its long-lived assets, such as property, plant and equipment and definite-lived intangible assets, for impairment in accordance with ASC 360, Property, Plant, and Equipment. In accordance with ASC 360, long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying amount may not be recoverable. The Company periodically reviews for indicators and, if indicators are present, tests the carrying amount of long-lived assets, assessing their recoverable value based on estimated undiscounted cash flows over their remaining estimated useful lives. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. If the carrying amount of an asset (or asset group) exceeds its estimated undiscounted future cash flows, an impairment charge is measured as the amount by which the carrying amount of the asset (or asset group) exceeds the fair value of the asset (or asset group, as applicable), based on discounted cash flows.

Assets held for sale and discontinued operations

Assets held-for-sale and discontinued operations

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph ASC 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria, the major current assets, other assets, current liabilities, and other liabilities are reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), are reported as components of net income (loss) separate from the net income (loss) of continuing operations.

The Company periodically evaluates its long-lived assets that it plans to dispose of through sale for held-for-sale classification. To be classified as held-for-sale, management must have committed to a plan to sell, the asset (or asset group) must be available for immediate sale in its present condition, an active program to locate a buyer must have been initiated, the sale must be probable to close within one year, the asset (or asset group) must be marketed at a reasonable sales price, and it must be unlikely that significant changes to the plan will be made. Once an asset (or asset group) meets all of the above criteria, it is reclassified as assets held-for-sale on the consolidated balance sheet, and the asset(s) cease depreciation and are written down to their fair value, less costs to sell, if applicable.

The Company completed a review of its global supply chain in 2023 and determined that it would wind down its Winnipeg, Manitoba facility (“Cronos Fermentation Facility”) and list it for sale. This review involved significant complexities and judgments in making the accounting treatment determination. There are subjective and complex judgments in the determination of whether the Cronos Fermentation Facility meets the criteria to be classified as held for sale, including: (1) whether the Cronos Fermentation Facility is available for sale in its present condition subject only to terms that are usual and customary for sales of such businesses, (2) whether the sale of the Cronos Fermentation Facility is probable and that the transfer of assets will be a completed sale within one year from period end, and (3) whether the Cronos Fermentation Facility is being actively marketed at a reasonable price. See Note 7 “Property, Plant and Equipment, net” for discussion regarding our evaluation of the Cronos Fermentation Facility for held-for-sale classification as of December 31, 2024.

Impairment of goodwill and indefinite-lived intangible assets

Impairment of goodwill and indefinite-lived intangible assetsGoodwill and indefinite-lived intangible assets are not amortized. Goodwill and indefinite-lived intangible assets are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value of the reporting unit has been reduced to less than its carrying amount in accordance with the provisions of ASC 350, Intangibles—Goodwill and Other. The Company performs an impairment test annually in the fourth quarter by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.

Income taxes

The Company uses the liability method of accounting for income taxes, under which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when such assets and liabilities are recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the year that includes the enactment date. The Company determines deferred tax assets including net operating losses and liabilities, based on temporary differences between the book and tax bases of assets and liabilities.

A valuation allowance is established to reduce some or all net deferred tax assets to amounts that are more likely than not to be realized. The Company considers all available evidence, both positive and negative, including past operating results, estimates of future taxable income, and the feasibility of tax planning strategies, in assessing the need for a valuation allowance.

A valuation allowance against some or all of the net deferred tax assets does not in any way impact the Company’s ability to use future tax deductions such as the Company’s net operating loss carryforwards; rather, the valuation allowance indicates, according to the provisions of ASC 740, Income Taxes, it is more likely than not that the deferred tax assets will not be realized. The valuation allowance that was established will be maintained until there is sufficient positive evidence to conclude that it is more likely than not that the net deferred tax assets will be realized. The Company’s income tax expense for future periods will be reduced to the extent of corresponding decreases in our valuation allowance. There is uncertainty regarding any future realization of the benefit by the Company of all or part of our net deferred tax assets.

Judgment is required to determine the recognition and measurement attributes prescribed in the accounting guidance for uncertainty in income taxes. The Company uses a two-step approach for evaluating uncertain tax positions. Step one, recognition, requires us to determine whether the weight of available evidence indicates that a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any. If a tax position is not considered “more likely than not” to be sustained, no benefits of the position are recognized. If we determine that a position is “more likely than not” to be sustained, then we proceed to step two, measurement, which is based on the largest amount of benefit which is more likely than not to be realized on effective settlement. This process involves estimating our actual current tax exposure, including assessing the risks associated with income tax audits, together with assessing temporary differences resulting from the different treatment of items for tax and financial reporting purposes. If actual results differ from our estimates, our net operating loss and credit carryforwards, to the extent not covered by a valuation allowance, could be materially impacted in the period which such determination is made.

The Company recognizes uncertain income tax positions at the largest amount that is more-likely-than-not to be sustained upon examination by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Recognition or measurement is reflected in the period in which the likelihood changes. Any interest and penalties related to unrecognized tax liabilities are presented within income tax expense in the consolidated statements of net income (loss) and comprehensive income (loss). Accrued interest and penalties are included in accounts payable and other liabilities in the consolidated balance sheets.

Foreign currency

The Company’s functional currency is the Canadian dollar (“C$”) and its reporting currency is the U.S. dollar. Functional currencies for the entities in these consolidated financial statements are their respective local currencies, including C$, U.S. dollar and Israeli New Shekel (“ILS”). All assets and liabilities of operations with a functional currency other than the Canadian dollar are translated into Canadian dollars at the period-end currency exchange rates and subsequently translated into U.S. dollars at period-end currency exchange rates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss), net of tax. Revenues and expenses of operations, as well as all cash flows, with a functional currency other than the Canadian dollar are translated into Canadian dollars at the average exchange rates for the period and subsequently translated into U.S. dollars at the average exchange rates for the period. Transaction gains and losses resulting from changes in foreign currency exchange rates are recorded in either cost of sales, general and administrative expenses, or foreign currency transaction gain (loss) in the consolidated statements of net income (loss) and comprehensive income (loss).

Segments

Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Historically, the Company reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment. All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Annual Report. These reclassifications had no effect on our consolidated financial statements in any period presented.

Earnings (loss) per share

The Company presents basic and diluted earnings (loss) per share data for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all potentially dilutive common shares.

Fair value measurements

The carrying amount of the Company’s cash and cash equivalents, accounts receivable, other receivables, loans receivable, accounts payable and other liabilities approximate fair value, given their short-term nature. Cronos uses a fair value hierarchy, which gives the

highest priority to unadjusted quoted prices in active markets for identical assets and liabilities, noted as Level 1 measurements, and the lowest priority to unobservable inputs, noted as Level 3 measurements.

The following are the three levels of inputs used to measure fair value:

•Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities.

•Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

•Level 3 – valuation techniques using the inputs for the asset or liability that are not based on observable market data.

The Company’s policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer.

Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted

Adoption of new accounting pronouncements

In the fourth quarter of 2024, the Company adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information on the CODM and disclosures for entities with a single reportable segment. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The adoption of ASU 2023-07 did not have an impact on the consolidated results of operations, financial condition or statement of cash flows.

On January 1, 2024, the Company adopted ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. The adoption of ASU 2022-03 did not have a material impact on the Company’s consolidated financial statements. With respect to the adoption of ASU 2022-03, see Note 5 “Investments” for discussion of the contractual restrictions related to the PharmaCann Option (as defined below).

(ab)New accounting pronouncements not yet adopted

In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2024-03”). ASU 2024-03 adds an obligation under ASC 220-40 to require a footnote disclosure about specific expenses by requiring public business entities to disaggregate, in a tabular presentation, each relevant expense caption on the face of the income statement that includes any of the following natural expenses: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depreciation, depletion, and amortization recognized as part of oil and gas-producing activities or other types of depletion expenses. The tabular disclosure would also include certain other expenses, when applicable. ASU 2024-03 does not change or remove existing expense disclosure requirements; however, it may affect where that information appears in the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted, and applicable entities are required to adopt ASU 2024-03 prospectively; however, companies are permitted to apply the amendments in ASU 2024-03 retrospectively. The Company does not expect the adoption of ASU 2024-03 to have a material impact on its consolidated financial statements. In January 2025, the effective date was further clarified with the issuance of ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. No guidance was changed with ASU 2025-01, but the issuance simply ensures that all public business entities have a clear and consistent timeline for implementing the enhanced expense disaggregation disclosures.

Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2025	$ 2,125
2026	1,479
2027	974
2028	800
2029	795
Thereafter	3,584
Net	$ 9,757	$ 19,578

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Valuation Allowance [Line Items]
Loss from discontinued operations	$ 0	$ (4,114)	$ (13,556)
Taxes payable, current	9	64	32,956
Taxes receivable, current	3,110	3,374	40
Valuation allowance	(200,284)	(216,241)
Unrecognized tax benefits	0	0
Research Tax Credit Carryforward
Valuation Allowance [Line Items]
Tax credit carryforward	4,165
Canada
Valuation Allowance [Line Items]
Operating loss carryforwards	197,515	253,521
Untied States
Valuation Allowance [Line Items]
Operating loss carryforwards	151,279	144,219
Israel
Valuation Allowance [Line Items]
Operating loss carryforwards	17,049	20,794
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset
Valuation Allowance [Line Items]
Valuation allowance increase (decrease)	(15,957)	2,042
Altria Warrant
Valuation Allowance [Line Items]
Capital gain on relinquishment of warrant			479,800
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Valuation Allowance [Line Items]
Loss from discontinued operations	$ 0	$ (4,114)	$ (13,556)

Property, Plant and Equipment, net - Schedule of Property Plant and Equipment Acquisition by Major Category (Details) - Cronos GrowCo - USD ($) $ in Thousands	Dec. 31, 2024	Jul. 01, 2024
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 87,630	$ 87,630
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment		4,557
Building and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment		49,356
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment		21,603
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment		580
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment		$ 11,534

Restructuring (Tables)

12 Months Ended

Dec. 31, 2024

Restructuring and Related Activities [Abstract]

Schedule of Plan Information and Restructuring-Related Costs

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of December 31, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of December 31, 2021		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2024 and 2023:


	As of December 31, 2023		Expenses		Payments/Write-offs		As of December 31, 2024
Employee Termination Benefits	$	150	$	62	$	(212)	$	—

Other Restructuring Costs	—		568		(568)		—
Total	$	150	$	630	$	(780)	$	—


	As of December 31, 2022		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150

Investments - Schedule of Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended						12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other Investments [Roll Forward]
Other investments, beginning balance		$ 35,251					$ 35,251	$ 70,993
Unrealized loss							(6,206)	(12,096)
Impairment charges							(25,650)	(23,350)	$ (61,392)
Foreign exchange effect							(582)	(296)
Other investments, ending balance			$ 35,251	$ 70,993			2,813	35,251	70,993
PharmaCann
Other Investments [Roll Forward]
Other investments, beginning balance		25,650					25,650	49,000
Unrealized loss							0	0
Impairment charges	$ (12,916)	(12,734)	(23,350)	(21,182)	$ (28,972)	$ (11,238)	(25,650)	(23,350)
Foreign exchange effect							0	0
Other investments, ending balance			25,650	49,000			0	25,650	49,000
Vitura
Other Investments [Roll Forward]
Other investments, beginning balance		$ 9,601					9,601	21,993
Unrealized loss							(6,206)	(12,096)
Impairment charges							0	0
Foreign exchange effect							(582)	(296)
Other investments, ending balance			$ 9,601	$ 21,993			$ 2,813	$ 9,601	$ 21,993

Discontinued Operations - Schedule of Restructuring Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Expenses	$ 630	$ 1,524	$ 3,545
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	0	0	0
Expenses		523	1,788
Payments/Write-offs		(523)	(1,788)
Accrual, ending balance		0	0
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	0	0	0
Expenses		431	1,788
Payments/Write-offs		(431)	(1,788)
Accrual, ending balance		0	0
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	$ 0	0
Expenses		92
Payments/Write-offs		(92)
Accrual, ending balance		$ 0	$ 0

Segment Information - Schedule of Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total cash and cash equivalents and short-term investments	$ 858,805	$ 861,528
Long-lived assets	133,189	59,498
Intangibles, net	11,257	21,078
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	117,329	41,513
Intangibles, net	10,887	20,531
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	15,860	17,985
Intangibles, net	$ 370	$ 547

Business Combination - Narrative (Details) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 01, 2024	Jan. 01, 2023	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024
Business Acquisition [Line Items]
Equity method investments			$ 0	$ 0	$ 0	$ 19,488
Gain on revaluation of equity method investment					32,469	0	$ 0
Gain on revaluation of loan receivable					11,804	0	0
Inventory step-up recorded to cost of sales					5,284	0	0
Goodwill			63,453	63,453	63,453	1,057
Net revenue, before excise taxes					161,821	120,270	$ 109,301
Cronos GrowCo
Business Acquisition [Line Items]
Equity method investments			0	0	0	19,488		$ 53,542
Cronos GrowCo
Business Acquisition [Line Items]
Loans receivable	$ 51,000
Supply agreement, right to purchase percent	80.00%
Supply agreement, right to purchase forecasted production percent	70.00%
Supply agreement, right to purchase actual production percent	70.00%
Gain on revaluation of equity method investment					32,469
Gain on revaluation of loan receivable					11,804
Fair value of noncontrolling interest	$ 53,542
Goodwill, decreased			28,848
intangible assets increased			8,008
Property, plant, and equipment decreased			31,970
Inventory adjustment	5,605		(15,287)
Deferred income tax liability decreased			10,401
Inventory	$ 15,754		15,754	15,754	15,754
Inventory step-up recorded to cost of sales				5,284	5,284
Revenue of acquiree since acquisition date					6,374
Loss of acquiree since acquisition date					802
Acquisition-related costs					701
Goodwill			$ 65,269	$ 65,269	65,269
Cronos GrowCo \| Fair Value Adjustment to Inventory
Business Acquisition [Line Items]
Inventory adjustment		$ 5,605				5,605
Cronos GrowCo \| Pre-Business Combination Revenue Adjustment
Business Acquisition [Line Items]
Net revenue, before excise taxes					14,776	21,145
Cost of goods and services sold					$ 11,386	$ 17,988

Discontinued Operations - Schedule of Major Components Comprising Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Net loss from discontinued operations	$ 0	$ (4,114)	$ (13,556)
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue		1,029	5,155
Cost of sales		2,164	8,622
Inventory write-down		839	0
Gross profit		(1,974)	(3,467)
Operating expenses
Sales and marketing		578	4,236
Research and development		32	250
General and administrative		668	3,504
Restructuring costs		523	1,788
Share-based compensation		13	107
Depreciation and amortization		13	58
Impairment loss on goodwill and indefinite-lived intangible assets		0	0
Impairment loss on long-lived assets		205	0
Total operating expenses		2,032	9,943
Interest income		10	23
Other, net		(118)	(169)
Total other loss		(108)	(146)
Loss before income taxes		(4,114)	(13,556)
Income tax expense (benefit)		0	0
Net loss from discontinued operations	$ 0	(4,114)	$ (13,556)
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment \| Facility in Los Angeles, California
Operating expenses
Impairment loss on long-lived assets		$ 205

Financial Instruments - Liquidity Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Concentration Risk [Line Items]
Accounts payable, trade, current	$ 4,563	$ 8,887
Accounts Payable \| Supplier Concentration Risk \| One Vendor
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	26.00%

Discontinued Operations

12 Months Ended

Dec. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. Accordingly, the net income (loss) for the years ended December, 31, 2023 and 2022 are reported separately as income (loss) from discontinued operations on the consolidated statements of net income (loss) and comprehensive income (loss). There was no activity in discontinued operations for the year ended December, 31, 2024.

The following table presents the major components comprising loss from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023, and 2022:


	Year ended December 31, 2023		Year ended December 31, 2022
Net revenue	$	1,029	$	5,155
Cost of sales	2,164		8,622
Inventory write-down(i)	839		—
Gross profit	(1,974)		(3,467)
Operating expenses
Sales and marketing	578		4,236
Research and development	32		250
General and administrative	668		3,504
Restructuring costs	523		1,788
Share-based compensation	13		107
Depreciation and amortization	13		58
Impairment loss on goodwill and indefinite-lived intangible assets	—		—
Impairment loss on long-lived assets(ii)	205		—
Total operating expenses	2,032		9,943
Interest income	10		23
Other, net(iii)	(118)		(169)
Total other loss	(108)		(146)
Loss before income taxes	(4,114)		(13,556)
Income tax expense (benefit)	—		—
Net loss from discontinued operations	(4,114)		(13,556)

(i)For the year ended December 31, 2023, Inventory write-down relates to the disposal of obsolete inventory as a result of the exit of the U.S. operations.

(ii)During the year ended December 31, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California.

(iii)For the years ended December 31, 2023 and December 31, 2022, other, net related to loss on disposal of assets that were part of the U.S. operations.

The following tables present the Company’s discontinued operations revenue by major product category:



	2023		2022
Cannabis extracts	1,029		5,155
Net revenue	$	1,029	$	5,155

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of December 31, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of December 31, 2021		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

As of December 31, 2023, there were no remaining assets or liabilities attributable to the Company’s discontinued operations.

For the years ended December 31, 2023 and 2022, purchases of property plant and equipment related to discontinued operations were $67 and $183, respectively.

The following table presents information related to leases associated with the Company’s U.S. discontinued operations. As of December 31, 2024 and December 31, 2023, the Company had no right-of-use assets or lease obligations associated with its U.S. discontinued operations. For the years ended December 31, 2023 and 2022, the aggregate depreciation expense on right-of-use assets associated with the Company’s U.S. discontinued operations was $198 and $865, respectively, and was included in loss from discontinued operations on the consolidated statements of net income (loss) and comprehensive income (loss).



	2023			2022
Lease cost
Operating lease cost	$	213		$	1,102
Short-term lease cost	—			—
Total lease cost	$	213		$	1,102

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	525		$	1,050
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			443

Weighted-average remaining lease term (years) – operating leases	0.0			1.0
Weighted-average discount rate – operating leases	—		%	5.62		%

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 12,411	$ 2,505	$ 3,451
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment		67	183
Depreciation expense on right-of-use assets		$ 198	$ 865

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

For financial reporting purposes, income (loss) from continuing operations before income taxes includes the following components:


	Year ended December 31,
	2024		2023		2022
Income (loss) before income taxes	$	36,586	$	(73,669)	$	(121,003)

The income (loss) before income taxes above excludes losses from discontinued operations of nil, $4,114 and $13,556 for the years ended December 31, 2024, 2023 and 2022, respectively.

Income tax expense (benefit) consists of the following components:


	Year Ended December 31,
	2024		2023		2022
Current	$	(3,170)	$	(3,375)	$	34,416
Deferred	(266)		145		(241)
Total	$	(3,436)	$	(3,230)	$	34,175

As of December 31, 2024, 2023 and 2022, the Company’s current income taxes payable were $9, $64 and $32,956, respectively, related to current income tax expense. Included in other receivables as of December 31, 2024, 2023 and 2022 is $3,110, $3,374 and $40, respectively, related to current income tax benefits.

Income tax differs from that computed using the combined Canadian federal and provincial statutory income tax rate of 26.5%. Reconciliation of the expected income tax to the effective tax rate in continuing operations is as follows:


	Year ended December 31,
	2024			2023				2022
Income (loss) before income taxes	$	36,586		$	(73,669)		$	$	(121,003)
Effective income tax rate	26.5		%	26.5		%		26.5		%
Expected income tax expense (benefit)	$	9,695		$	(19,522)			$	(32,066)

Non-taxable income (loss)	(11,138)			1,077				(2,140)
Non-deductible share-based compensation	143			525				1,198
Non-deductible expenses	741			459				836
Non-deductible transaction costs	(14)			351				1,625
Effect of provincial tax rate difference	(66)			(9)				(15)
Effect of tax rates outside of Canada	755			816				1,848
Effect of change in tax rates	11,533			4,601				11,041
Fair value gain (loss) on financial liabilities	(15)			23				(3,726)
Changes in valuation allowance	(19,367)			7,930				(10,466)
Capital gain on financial liabilities	—			106				66,193
Additional taxable income	3,746			—				—
Other	551			413				(153)
Income tax expense (benefit), net	$	(3,436)		$	(3,230)			$	34,175

The valuation allowance recorded against the loss on discontinued operations is not reflected in the effective tax rate reconciliation presented above for continuing operations.

For the year ended December 31, 2022, the Company realized a capital gain for tax purposes of $479,800 as a result of Altria’s irrevocable relinquishment of its warrant on December 16, 2022, resulting in an increase in the total income tax expense reported for the year ended December 31, 2022.

The following table summarizes the significant components of the Company’s deferred tax assets and liabilities:


	As of December 31,
	2024		2023
Deferred tax assets:
Tax loss carryforwards	$	96,349	$	111,516
Interest expense carryforwards	2,814		2,688


Finance lease obligation	306		519
Plant and equipment	32,130		36,697
Investment	28,778		19,745
Intangible assets	36,428		37,203
Inventory	419		556
Reserve	1,282		2,430
Unrealized foreign exchange	—		275
R&D investment tax credits	1,104		567
Other	3,245		4,271
Total deferred tax assets	202,855		216,467
Less valuation allowance	(200,284)		(216,241)
Net deferred tax assets	2,571		226
Deferred tax liabilities:

Plant and equipment	(1,635)		—
Intangible assets	(1,929)		—


Right-of-use assets	—		(181)

Total deferred tax liabilities	(3,564)		(181)
Net deferred tax asset (liability)	$	(993)	$	45

The realization of deferred tax assets is dependent on the Company’s generating sufficient taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the deferred tax assets that the Company determined did not meet the more-likely-than-not recognition threshold under U.S. GAAP.

As of December 31, 2024 and 2023, the Company’s valuation allowance was $200,284 and $216,241, respectively. The valuation allowance decreased by $15,957 during the year ended December 31, 2024, and increased by $2,042 during the year ended December 31, 2023. The decrease in the valuation allowance during the year ended December 31, 2024 was primarily due to the recognition of a portion of deferred tax assets for which a valuation allowance was recorded in the prior year. The increase in the valuation allowance during the year ended December 31, 2023, was primarily due to an increase in net operating loss carryforwards.

As of December 31, 2024, the Company had net operating losses in Canada, the U.S., and Israel available to offset future years’ taxable income of approximately $197,515, $151,279, $17,049, respectively. As of December 31, 2023, the Company had net operating losses in Canada, the U.S., and Israel available to offset future years’ taxable income of approximately $253,521, $144,219, and $20,794, respectively. The net operating losses in Canada will begin to expire, for purposes of carryforward, in fiscal year 2033. The net operating losses in the U.S. can be carried forward indefinitely for federal purposes. The net operating losses in Israel can be carried forward indefinitely.

Utilization of the net operating loss carryforwards may be subject to limitations under the tax laws applicable in each tax jurisdiction due to ownership changes that could occur in the future. These ownership changes could limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax expense. Due to the existence of the valuation allowance, limitations created by ownership changes, if any, will not impact the Company’s effective tax rate.

As of December 31, 2024, the Company has various scientific research and experimental development investment tax credit carryforwards of $4,165 related to Canadian operations, which, if not utilized, will begin to expire in 2040. Investment tax credits are recognized when realization of the tax credits is more likely than not.

The Company files federal income tax returns in Canada, Israel and the U.S. The Company has open tax years with the taxation jurisdictions. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenue and expense. As of December 31, 2024, Cronos Group USA Holdings Company Limited, a former wholly-owned subsidiary of the Company, is under examination with the Canadian Revenue Agency for tax years 2020 and 2021.


Jurisdiction						Open Years
Canada						2020 - 2024
United States						2021 - 2024
Israel						2021 - 2024

Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold may be recognized. There were no identified unrecognized tax benefits as of December 31, 2024 or December 31, 2023.

As of December 31, 2024 and 2023, deferred income taxes have not been provided for any undistributed earnings from operations outside of Canada. The foreign subsidiaries have accumulated losses and as such the amount of undistributed earnings upon which income taxes have not been provided is immaterial to these consolidated financial statements.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Consolidated Statements of Changes in Shareholders’ Equity - USD ($) $ in Thousands	Total	Share capital and additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2021		374,952,693
Beginning balance at Dec. 31, 2021	$ 1,334,276	$ 627,962	$ 659,416	$ 49,865	$ (2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		1,464,822
Activities relating to share-based compensation	14,834	$ 14,834	0
Share issuance pursuant to research and development milestone (in shares)		4,157,888
Share issuance pursuant to research and development milestones	11,204	$ 11,204
Net income (loss)	(168,734)		(168,734)		0
Foreign exchange gain (loss) on translation	(50,616)			(50,662)	46
Ending balance (in shares) at Dec. 31, 2022		380,575,403
Ending balance at Dec. 31, 2022	1,140,964	$ 654,000	490,682	(797)	(2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		723,450
Activities relating to share-based compensation	8,174	$ 8,174
Net income (loss)	(74,553)		(73,963)		(590)
Foreign exchange gain (loss) on translation	$ 21,539			21,475	64
Ending balance (in shares) at Dec. 31, 2023	381,298,853	381,298,853
Ending balance at Dec. 31, 2023	$ 1,096,124	$ 662,174	416,719	20,678	(3,447)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Non-controlling interest resulting from business combination	53,542				53,542
Activities relating to share-based compensation (in shares)		1,231,927
Activities relating to share-based compensation	7,615	$ 7,705	(90)
Net income (loss)	40,022		41,080		(1,058)
Foreign exchange gain (loss) on translation	$ (86,321)			(84,203)	(2,118)
Ending balance (in shares) at Dec. 31, 2024	382,530,780	382,530,780
Ending balance at Dec. 31, 2024	$ 1,110,982	$ 669,879	$ 457,709	$ (63,525)	$ 46,919

Goodwill and Intangible Assets, net - Schedule of Impairment Charges on Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	$ (14,696)
Ending balance	(27,019)	$ (14,696)
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(77,338)	(73,650)	$ (74,308)
Impairment charges	(14,258)	(3,366)	(76)
Foreign exchange effect	1,935	(322)	734
Ending balance	(89,661)	(77,338)	(73,650)
Lord Jones brand
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(62,500)	(62,500)	(62,500)
Impairment charges	0	0	0
Ending balance	(62,500)	(62,500)	(62,500)
Trademarks
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(142)	(142)	(142)
Impairment charges	0	0	0
Ending balance	(142)	(142)	(142)
Software
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(78)	(76)	(4)
Impairment charges	0	0	(76)
Foreign exchange effect	6	(2)	4
Ending balance	(72)	(78)	(76)
Health Canada licenses
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(6,650)	(6,498)	(6,910)
Impairment charges	0	0	0
Foreign exchange effect	513	(152)	412
Ending balance	(6,137)	(6,650)	(6,498)
Ginkgo exclusive licenses
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(7,968)	(4,434)	(4,752)
Impairment charges	(14,258)	(3,366)	0
Foreign exchange effect	1,416	(168)	318
Ending balance	$ (20,810)	$ (7,968)	$ (4,434)

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]
Loss on held-for-sale assets		$ 11,202	$ 0	$ 0
Restructuring costs		630	1,524	3,545
Inventory write-down		707	805	$ 0
Realignment
Restructuring Cost and Reserve [Line Items]
Impairment loss on long-lived assets		1,631
Loss on held-for-sale assets	$ 345	10,422
Restructuring costs		630	$ 1,524
Inventory write-down		805
Realignment \| Disposal Group, Held-for-Sale, Not Discontinued Operations \| Cronos Fermentation
Restructuring Cost and Reserve [Line Items]
Current assets of discontinued operations	$ 8,112	$ 8,112			$ 19,398

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Related Party Transactions

12 Months Ended

Dec. 31, 2024

Related Party Transactions

(a)Altria

On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company. As of December 31, 2024, Altria beneficially held an approximately 40.9% ownership interest in the Company (calculated on a non-diluted basis).

There were no amounts payable related to the consulting services with Altria Pinnacle as of December 31, 2024 and 2023.

Refer to Note 10 “Derivative Liabilities” for further information on the derivative liabilities related to the Altria Investment.

(b)Cronos GrowCo

The Company holds both ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo and these were historically accounted for as related party transactions. Effective July 1, 2024, the Company obtained majority control of the board of directors of Cronos GrowCo, which is now accounted for as an intercompany relationship and all intercompany activity is eliminated upon consolidation. For more information on the GrowCo Transaction, See Note 2“Business Combination” for further information regarding the Cronos GrowCo Transaction.

The Company made the following purchases of cannabis products from Cronos GrowCo:


	Year ended December 31,
	2024(i)		2023		2022
Cronos GrowCo – purchases	$	16,952	$	21,335	$	18,144

(i)2024 activity presented above represents purchases from Cronos GrowCo for the first six months of the year.

The Company’s outstanding payable balance to Cronos GrowCo was $2,267 as of December 31, 2023.

During the third quarter of 2023, the Company, as supplier, entered into a cannabis germplasm supply agreement with Cronos GrowCo as buyer. During 2023, the Company received proceeds of $1,114 in relation to this agreement.

Also, during 2023, the Company sold certain held for sale assets with carrying value of $332 and certain other previously expensed assets with a zero net book value to Cronos GrowCo for total proceeds of $761 and recognized a $436 gain in other, net in the consolidated statements of net income (loss) and comprehensive income (loss).

Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Credit Facility. See Note 6 “Loans Receivable, net” for further information regarding the GrowCo Credit Facility.

(c)Vendor Agreement

In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another vendor whose chief executive officer is an immediate family member of an executive of the Company. The Company purchased $0 and $2,310 of products and services under this subcontracted agreement for the years ended December 31, 2024 and December 31, 2023, respectively. The company had $0 in outstanding accounts payables related to the subcontracted agreement as of December 31, 2024 and $28 in outstanding accounts payable related to the subcontracted agreement as of December 31, 2023.

In November 2023, the Company negotiated a direct contract with the related-party vendor. During the years ended 2024 and 2023, the Company purchased $1,746 and $42 of products and services directly from the related-party vendor and had $149 and $11 in outstanding accounts payable to the vendor as of December 31, 2024 and 2023, respectively.

(d)Consulting Agreement

In connection with the Cronos GrowCo Transaction, Cronos GrowCo entered into a consulting services agreement with a consulting firm managed by a member of the group of investors holding the remaining 50% ownership of Cronos GrowCo, pursuant to which the consulting firm provides management services to Cronos GrowCo. During the year ended December, 31 2024, the Company incurred $434 of expense under this agreement. As of December 31, 2024, the Company had no outstanding payables related to this agreement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue, before excise taxes	$ 161,821	$ 120,270	$ 109,301
Excise taxes	(44,206)	(33,029)	(22,552)
Net revenue	117,615	87,241	86,749
Cost of sales	91,710	74,527	71,313
Inventory write-down	707	805	0
Gross profit	25,198	11,909	15,436
Operating expenses
Sales and marketing	21,603	22,701	18,046
Research and development	4,229	5,843	13,131
General and administrative	46,514	49,475	67,674
Restructuring costs	630	1,524	3,545
Share-based compensation	8,700	8,756	15,008
Depreciation and amortization	3,701	5,044	5,967
Impairment loss on long-lived assets	16,350	3,366	3,493
Total operating expenses	101,727	96,709	126,864
Operating loss	(76,529)	(84,800)	(111,428)
Other income (expense)
Interest income, net	52,019	51,235	22,514
Gain (loss) on revaluation of derivative liabilities	49	(85)	14,060
Share of income from equity method investments	2,365	1,583	3,114
Gain on revaluation of loan receivable	11,804	0	0
Gain on revaluation of equity method investment	32,469	0	0
Gain (loss) on revaluation of financial instruments	(6,248)	(12,042)	14,739
Impairment loss on other investments	(25,650)	(23,350)	(61,392)
Foreign currency transaction gain (loss)	57,859	(7,324)	(2,286)
Loss on held-for-sale assets	(11,202)	0	0
Other, net	(350)	1,114	(324)
Total other income (expense)	113,115	11,131	(9,575)
Income (loss) before income taxes	36,586	(73,669)	(121,003)
Income tax expense (benefit)	(3,436)	(3,230)	34,175
Income (loss) from continuing operations	40,022	(70,439)	(155,178)
Loss from discontinued operations	0	(4,114)	(13,556)
Net income (loss)	40,022	(74,553)	(168,734)
Net income (loss) attributable to non-controlling interest	(1,058)	(590)	0
Net income (loss) attributable to Cronos Group	41,080	(73,963)	(168,734)
Comprehensive income (loss)
Net income (loss)	40,022	(74,553)	(168,734)
Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	(86,321)	21,539	(50,616)
Comprehensive income (loss)	(46,299)	(53,014)	(219,350)
Comprehensive income (loss) attributable to non-controlling interest	(3,176)	(526)	46
Comprehensive income (loss) attributable to Cronos Group	$ (43,123)	$ (52,488)	$ (219,396)
Net income (loss) per share
Basic - continuing operations (in dollars per share)	$ 0.11	$ (0.18)	$ (0.41)
Basic - discontinued operations (in dollars per share)	0	(0.01)	(0.04)
Basic net income (loss) per share attributable to Cronos Group (in dollars per share)	0.11	(0.19)	(0.45)
Diluted - continuing operations (in dollars per share)	0.11	(0.18)	(0.41)
Diluted - discontinued operations (in dollars per share)	0	(0.01)	(0.04)
Diluted net income (loss) per share attributable to Cronos Group (in dollars per share)	$ 0.11	$ (0.19)	$ (0.45)

Leases

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Leases

The Company has entered into leases primarily for the land-use rights, office and research premises and equipment used in the production of cannabis and other related products. The Company’s leases have terms that range from 19 months to six years, excluding land use rights, which generally extend to 15 years. These leases often include options to extend the term of the lease for up to 10 years. When it is reasonably certain that the option will be exercised, the impact of the option is included in the lease term for purposes of determining total future lease payments.

Operating leases greater than one year are included in right-of-use assets and operating lease liabilities. Finance leases are included in property, plant and equipment on the Company’s consolidated balance sheet. The Company’s finance leases were not material for any of the periods presented.


	As of December 31,
	2024			2023			2022
Lease cost
Operating lease cost	$	613		$	685		$	1,107
Short-term lease cost	—			—			—
Total lease cost	$	613		$	685		$	1,107

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	1,137		$	1,124		$	1,441
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	566			—			—

Weighted-average remaining lease term (years) – operating leases	3.6			3.6			4.3
Weighted-average discount rate – operating leases	7.71		%	7.62		%	7.39		%

For the years ended December 31, 2024, 2023 and 2022, the aggregate depreciation expense on right-of-use assets was $486, $455 and $839, respectively, and was included in general and administrative expenses on the consolidated statements of net income (loss) and comprehensive income (loss).

During the year ended December 31, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease.

The following is a summary of the Company’s future minimum lease payments under operating leases for its premises due in future fiscal years:


	As of December 31, 2024
2025	$	1,146
2026	382
2027	229
2028	229
2029	96
Thereafter	319
Total lease payments	2,401
Less: imputed interest	(383)
Present value of lease liabilities	$	2,018

In addition to the minimum lease payments, the Company is required to pay realty taxes and other occupancy costs in accordance with the terms of the lease agreements.

Business Combination - Schedule of Intangible Assets Acquired (Details) - Cronos GrowCo $ in Thousands	Jul. 01, 2024 USD ($)
Business Acquisition [Line Items]
Fair value at date of acquisition	$ 8,008
Amortization period (in years)	10 years
Know-How
Business Acquisition [Line Items]
Fair value at date of acquisition	$ 8,008

Discontinued Operations - Schedule of Lease Information Associated with Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lease cost
Operating lease cost	$ 613	$ 685	$ 1,107
Short-term lease cost	0	0	0
Total lease cost	613	685	1,107
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	1,137	1,124	1,441
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	$ 566	$ 0	$ 0
Weighted-average remaining lease term (years) – operating leases	3 years 7 months 6 days	3 years 7 months 6 days	4 years 3 months 18 days
Weighted-average discount rate – operating leases	7.71%	7.62%	7.39%
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Lease cost
Operating lease cost		$ 213	$ 1,102
Short-term lease cost		0	0
Total lease cost		213	1,102
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations		525	1,050
Non-cash activity - right-of-use assets obtained in exchange for lease obligations		$ 0	$ 443
Weighted-average remaining lease term (years) – operating leases		0 years	1 year
Weighted-average discount rate – operating leases		0.00%	5.62%

Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Data and Adjusted EBITDA

The tables below set forth consolidated Adjusted EBITDA and significant expenses for our single segment:


	Year ended December 31,
	2024		2023		2022
Adjusted EBITDA	$	(34,942)	$	(63,746)	$	(80,608)

Significant expenses:
Sales and marketing	21,603		22,701		18,046
Research and development	4,229		5,843		13,131
General and administrative	46,514		49,475		67,674
Share-based compensation	8,700		8,756		15,008
Depreciation and amortization	3,701		5,044		5,967
Total significant expenses	84,747		91,819		119,826
Restructuring costs	630		1,524		3,545
Impairment loss on long-lived assets	16,350		3,366		3,493
Total operating expense	$	101,727	$	96,709	$	126,864

The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated:


(in thousands of U.S. dollars)	For the year ended December 31, 2024
	Continuing Operations		Discontinued Operations		Total
Net income	$	40,022	$	—	$	40,022
Interest income, net	(52,019)		—		(52,019)
Income tax benefit	(3,436)		—		(3,436)
Depreciation and amortization	9,336		—		9,336
EBITDA	(6,097)		—		(6,097)
Share of income from equity method investments	(2,365)		—		(2,365)
Impairment loss on long-lived assets(i)	16,350		—		16,350
Revaluation gain on loan receivable(ii)	(11,804)		—		(11,804)
Gain on revaluation of equity method investment(iii)	(32,469)		—		(32,469)
Gain on revaluation of derivative liabilities(iv)	(49)		—		(49)
Loss on revaluation of financial instruments(v)	6,248		—		6,248
Impairment loss on other investments(vi)	25,650		—		25,650
Foreign currency transaction gain	(57,859)		—		(57,859)
Transaction costs(vii)	701		—		701
Loss on held-for-sale assets(viii)	11,202		—		11,202
Other, net(ix)	350		—		350
Restructuring costs(x)	630		—		630
Share-based compensation(xi)	8,700		—		8,700
Financial statement review costs(xii)	(1)		—		(1)

Inventory step-up recorded to cost of sales(xiv)	5,284		—		5,284
Israel Ministry of Economy and Industry dumping inquiry expense(xv)	587		$	—	587
Adjusted EBITDA	$	(34,942)	$	—	$	(34,942)


(in thousands of U.S. dollars)	For the year ended December 31, 2023
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(70,439)	$	(4,114)	$	(74,553)
Interest income, net	(51,235)		(10)		(51,245)
Income tax benefit	(3,230)		—		(3,230)
Depreciation and amortization	7,866		244		8,110
EBITDA	(117,038)		(3,880)		(120,918)
Share of income from equity method investments	(1,583)		—		(1,583)
Impairment loss on long-lived assets(i)	3,366		205		3,571
Loss on revaluation of derivative liabilities(iv)	85		—		85
Loss on revaluation of financial instruments(v)	12,042		—		12,042
Impairment loss on other investments(vi)	23,350		—		23,350
Foreign currency transaction loss	7,324		—		7,324
Other, net(ix)	(1,114)		118		(996)
Restructuring costs(x)	1,524		523		2,047
Share-based compensation(xi)	8,756		13		8,769
Financial statement review costs(xii)	919		—		919
Inventory write-down(xiii)	805		839		1,644
Adjusted EBITDA	$	(61,564)	$	(2,182)	$	(63,746)


(in thousands of U.S. dollars)	For the year ended December 31, 2022
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(155,178)	$	(13,556)	$	(168,734)
Interest income, net	(22,514)		(23)		(22,537)
Income tax expense	34,175		—		34,175
Depreciation and amortization	11,924		1,198		13,122
EBITDA	(131,593)		(12,381)		(143,974)
Share of income from equity method investments	(3,114)		—		(3,114)
Impairment loss on long-lived assets(i)	3,493		—		3,493
Gain on revaluation of derivative liabilities(iv)	(14,060)		—		(14,060)
Gain on revaluation of financial instruments(v)	(14,739)		—		(14,739)
Impairment loss on other investments(vi)	61,392		—		61,392
Foreign currency transaction loss	2,286		—		2,286
Other, net(ix)	324		169		493
Restructuring costs(x)	3,545		1,788		5,333
Share-based compensation(xi)	15,008		107		15,115
Financial statement review costs(xii)	7,167		—		7,167
Adjusted EBITDA	$	(70,291)	$	(10,317)	$	(80,608)

(i)For the year ended December 31, 2024, impairment loss on long-lived assets included $14,258 related to the write-down of our Ginkgo exclusive licenses and $1,631 related to the cessation of operations of Cronos Fermentation. For the year ended December 31, 2023, impairment loss on long-lived assets related to certain leased properties associated with the Company’s former U.S. operations and impairment of the Ginkgo Collaboration Agreement’s CBCVA exclusive license. For the year ended December 31, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. See Note 7 “Property, Plant and Equipment, net” and Note 8 “Goodwill and Intangible Assets, net.”

(ii)For the year ended December 31, 2024, a revaluation gain on loan receivable was recognized as a result of the Cronos GrowCo Transaction on July 1, 2024.

(iii)For the year ended December 31, 2024, a gain on revaluation of equity method investment was recognized as a result of the Cronos GrowCo Transaction on July 1, 2024.

(iv)For the years ended December 31, 2024, 2023 and 2022, the (gain) loss on revaluation of derivative liabilities represented the fair value changes on the derivative liabilities. See Note 10 “Derivative Liabilities.”

(v)For the years ended December 31, 2024, 2023 and 2022, (gain) loss on revaluation of financial instruments related primarily to our unrealized (gain) or loss (as applicable) on our mark-to-market investment in Vitura as well as revaluations of financial liabilities resulting from DSUs granted to directors. See Note 5 “Investments” and Note 11 “Share-based Compensation.”

(vi)For the years ended December 31, 2024, 2023 and 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 5 “Investments.”

(vii)For the year ended December 31, 2024, transaction costs represented legal, financial and other advisory fees and expenses incurred in connection with the Cronos GrowCo Transaction. These costs are included in general and administrative expenses on the consolidated statements of net income (loss) and comprehensive income (loss).

(viii)For the year ended December 31, 2024, a loss on held-for-sale assets was recognized as a result of the change in the Company’s sales strategy for the Cronos Fermentation assets to market the assets to a broader buyer pool.

(ix)For the years ended December 31, 2024, 2023 and 2022, other, net primarily related to (gain) loss on disposal of assets.

(x)For the year ended December 31, 2024, restructuring costs from continuing operations related to shutdown costs at the Cronos Fermentation Facility, as well as employee-related severance costs associated with the Realignment, as described in Note 18 “Restructuring.” For the years ended December 31, 2023 and 2022 restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment. See Note 18 “Restructuring.”

(xi)For the years ended December 31, 2024, 2023 and 2022, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under our share-based award plans, as described in Note 11 “Share-based Compensation.”

(xii)For the years ended December 31, 2024, 2023 and 2022, financial statement review costs included costs related to the Restatements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to the Restatements, the costs related to the Settlement Order and Settlement Agreement and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement as well as related insurance reimbursements.

(xiii)For the year ended December 31, 2023, inventory write-downs from discontinued operations related to product destruction and obsolescence associated with the exit of our U.S. operations as described in Note 3 “Discontinued Operations” and inventory write-downs from continuing operations related to product destruction and obsolescence associated with the planned exit of Cronos Fermentation as described in Note 18 “Restructuring.”

(xiv)For the year ended December 31, 2024, inventory step-up recorded to cost of sales represented the portion of the inventory step-up from the Cronos GrowCo Transaction that was recorded through the consolidated statements of income (loss) and comprehensive income (loss) in both periods.

(xv)For the year ended December 31, 2024, Israel Ministry of Economy and Industry dumping inquiry expense included expenditures relating to the regulatory inquiry about alleged dumping of medical cannabis products in Israel and related litigation and external relations expenses.

Schedule of Revenue from External Customers by Geographic Areas

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

The following table presents the Company’s revenue by major product category for our single segment:


	Year ended December 31,
	2024		2023		2022
Cannabis flower	$	87,912	$	62,070	$	63,593
Cannabis extracts	29,168		24,569		22,522
Other	535		602		634
Net revenue	$	117,615	$	87,241	$	86,749

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

Schedule of Property, Plant and Equipment, Net and Intangibles, Net Assets by Geographic Areas

The table below sets forth total cash and cash equivalents and short-term investments for our single segment:


	As of December 31,
	2024		2023
Total cash and cash equivalents and short-term investments	$	858,805	$	861,528

Property, plant and equipment, net were physically located in the following geographic regions:


	As of December 31,
	2024		2023
Canada	$	117,329	$	41,513

Israel	15,860		17,985
Total	$	133,189	$	59,498

Intangibles, net were physically located in the following geographic regions:


	As of December 31,
	2024		2023
Canada	$	10,887	$	20,531

Israel	370		547
Total	$	11,257	$	21,078

Commitments and Contingencies - Contingencies (Details) ₪ in Thousands, $ in Thousands	May 16, 2024 ILS (₪)	Apr. 17, 2023 ILS (₪) defendant	Oct. 24, 2022 CAD ($)	Mar. 12, 2020 shareholder complaint
U.S. District Court of Eastern District of New York Vs. Cronos \| Pending Litigation
Loss Contingencies [Line Items]
Number of alleged shareholders \| shareholder				2
Number of putative class action complaints \| complaint				2
OSC Settlement \| Settled Litigation
Loss Contingencies [Line Items]
Payments for legal settlements \| $			$ 1,340
Green Leaf Vs. Cronos
Loss Contingencies [Line Items]
Number of defendants \| defendant		26
Damages sought \| ₪		₪ 420,000
Amount awarded to other party \| ₪	₪ 10
Green Leaf Vs. Cronos \| Cronos Group, Inc.
Loss Contingencies [Line Items]
Number of defendants \| defendant		3

Share-based Compensation - Schedule of Restricted Share Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Weighted average grant date fair value
Balance at beginning of period (in dollars per share)	$ 3.77	$ 4.63
Granted (in dollars per share)	2.92	2.64
Vested and issued (in dollars per share)	3.49	5.00
Cancellation and forfeitures (in dollars per share)	3.18	3.60
Balance at end of period (in dollars per share)	$ 3.50	$ 3.77
Number of RSUs
Balance at beginning of period (in shares)	7,381,541	5,725,470
Granted (in shares)	2,987,147	3,292,586
Vested and issued (in shares)	(1,726,230)	(1,041,097)
Cancellation and forfeitures (in shares)	(260,245)	(595,418)
Balance at end of period (in shares)	8,382,213	7,381,541
Vesting period	3 years
Minimum
Number of RSUs
Cliff period	3 years
Maximum
Number of RSUs
Cliff period	5 years

Inventory, net - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 01, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Inventory step-up recorded to cost of sales				$ 5,284	$ 0	$ 0
Cronos GrowCo
Business Acquisition [Line Items]
Inventory adjustment	$ 5,605	$ (15,287)
Inventory step-up recorded to cost of sales			$ 5,284	$ 5,284

Income (Loss) per Share (Tables)

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Schedule of Earnings (Loss) Per Share

Basic and diluted earnings (loss) per share from continued and discontinued operations are calculated as follows:


	Year ended December 31,
	2024		2023		2022
Basic income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$	41,080	$	(69,849)	$	(155,178)
Weighted-average number of common shares outstanding for computation for basic income (loss) per share	382,058,056		380,964,739		376,961,797
Basic income (loss) from continuing operations per share	$	0.11	$	(0.18)	$	(0.41)


Loss from discontinued operations attributable to the shareholders of Cronos Group	$	—	$	(4,114)	$	(13,556)
Weighted-average number of common shares outstanding for computation of basic loss from discontinued operations per share	382,058,056		380,964,739		376,961,797
Basic loss from discontinued operations per share	$	—	$	(0.01)	$	(0.04)


Diluted income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$	41,080	$	(69,849)	$	(155,178)



Weighted-average number of common shares outstanding used in the computation of basic income (loss) per share	382,058,056		380,964,739		376,961,797


Dilutive effect of RSUs	3,243,564		—		—

Dilutive effect of Top-up Rights – market price	255,382		—		—
Weighted-average number of common shares for computation of diluted income (loss) from continuing operations per share(i)	385,557,002		380,964,739		376,961,797
Diluted income (loss) from continuing operations per share	$	0.11	$	(0.18)	$	(0.41)

Loss from discontinued operations attributable to the shareholders of Cronos Group	$	—	$	(4,114)	$	(13,556)
Weighted-average number of common shares for computation of diluted loss from discontinued operations per share	382,058,056		380,964,739		376,961,797
Diluted loss from discontinued operations per share	$	0.00	$	(0.01)	$	(0.04)

(i)In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2024	Feb. 24, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	4491 Concession Rd 12
Entity Address, City or Town	Stayner
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	L0M 1S0
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Financial Statement Error Correction [Flag]	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 458.2
Entity Common Stock, Shares Outstanding (in shares)		382,530,780
Documents Incorporated by Reference	Certain information required by Part III of this Annual Report on Form 10-K will either be incorporated into this Annual Report on Form 10-K by reference to the registrant’s definitive proxy statement for its 2025 Annual Meeting of Shareholders, or will be included in an amendment to this Annual Report on Form 10-K to be filed no later than 120 days after the registrant's fiscal year ended December 31, 2024.
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0001656472
Entity Tax Identification Number	00-0000000

Financial Instruments

12 Months Ended

Dec. 31, 2024

Risks and Uncertainties [Abstract]

Financial Instruments

(a)Fair value measurement

The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:

•Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.

•Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.


	As of December 31, 2024
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	858,805	$	—	$	—	$	858,805

Other investments(i)	2,813		—		—		2,813
Derivative liabilities	—		—		40		40


	As of December 31, 2023
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	669,291	$	—	$	—	$	669,291
Short-term investments	192,237		—		—		192,237
Other investments(i)	9,601		—		—		9,601
Derivative liabilities	—		—		102		102

There were no transfers between fair value categories during the periods presented.

As of December 31, 2024

Level 1

Level 2

Level 3

Total

Other investments(i)

—


	As of December 31, 2023
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	25,650	25,650

(i)Other investments measured at fair value on a non-recurring basis relate to our investment in PharmaCann. See Note 5 “Investments”.

There were no transfers between fair value categories during the periods presented.

(b)Financial risks

The Company’s activities expose it to a variety of financial risks, including credit risk, liquidity risk, market risk, interest rate risk, and foreign currency rate risk.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $904,101 and $966,442 as of December 31, 2024 and December 31, 2023, respectively.

(i)Accounts receivable

The Company had accounts receivable of $15,462 and $13,984 as of December 31, 2024 and December 31, 2023, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan, and a failure to make contractual payments for a period of greater than 120 days past due. As of December 31, 2024 and 2023, the Company had $7 and $3, respectively, in expected credit losses on receivables from contracts with customers.

The Company considers a major customer to be one with an accounts receivable balance of at least 10% of the consolidated total. As of December 31, 2024, the Company has assessed that there is a concentration risk of customers because 27% of accounts receivable was due from one customer. As of December 31, 2023, the Company has assessed that there is a concentration risk of customers because 37% of accounts receivable was due from one customer.

The Company sells products through a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenues. During the year ended December 31, 2024, the Company earned a total net revenue before excise taxes of $78,627 from two major customers, together accounting for 49% of the Company’s total net revenue before excise taxes. During the year ended December 31, 2023, the Company earned a total net revenue before excise taxes of $79,503 from three major customers, together accounting for 66% of the Company’s total net revenue before excise taxes. During the year ended December 31, 2022, the Company earned a total net revenue before excise taxes of $63,509 from three major customers, accounting for 55% of the Company’s total net revenues before excise taxes.

(ii) Cash and cash equivalents, short-term investments, and other receivables

The Company held cash and cash equivalents of $858,805 and $669,291 as of December 31, 2024 and December 31, 2023, respectively. The short-term investments and related interest receivable of $0 and $192,237 as of December 31, 2024 and December 31, 2023, respectively, represent short-term investments with a maturity of less than a year and accrued interest. The cash and cash equivalents and short-term investments, including guaranteed investment certificates and bankers’ acceptances, are held with central banks and financial institutions that are highly rated. In addition to interest receivable, other receivables include sales taxes receivable from the government. As such, the Company has assessed an insignificant loss allowance on these financial instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due and arises principally from the Company’s accounts payable. The Company had trade accounts payable of $4,563 and $8,887 as of December 31, 2024 and December 31, 2023, respectively, included in accounts payable on the consolidated balance sheet. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.

The Company considers a major vendor to be one with a trade accounts payable balance of at least 10% of the consolidated total. As of December 31, 2024, the Company has assessed that there is a concentration risk of vendors because 10% of accounts payable was due to one vendor. As of December 31, 2023, the Company has assessed that there is a concentration risk of vendors because 26% of accounts payable was due to one vendor.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to market risk in divesting its investments, such that unfavorable market conditions could result in dispositions of investments at less than their carrying amounts. Further, the revaluation of securities classified as fair value through net income could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s results of operations, unless these would flow through other comprehensive income.

The Company manages risk by having a portfolio of securities from multiple issuers, such that the Company was not materially exposed to any one issuer.

Interest rate risk

Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of income and expense recorded on the cash equivalents and short-term investments, and the market value of all interest-earning assets, other than those that possess a short term to maturity. A 10% change in the interest rate in effect on December 31, 2024 would not have a material effect on the fair value of our cash equivalents and short-term investments as the majority of the portfolio had a maturity date of three months or less. A 10% change in the interest rate in effect for 2024 would have an effect of $5.2 million on interest income, net earned on our cash equivalents and short-term investments. A 10% change in the interest rate in effect on December 31, 2023, would not have a material effect on fair value of the cash equivalents and short-term investments as the majority of the portfolio had a maturity date of three months or less. During the years ended December 31, 2024 and December 31, 2023, the Company had net interest income of $52,019 and $51,235, respectively.

Foreign currency risk

Currency rate risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on investments in equity investments denominated in A$ and C$, and other assets and liabilities denominated in A$ and C$. The Company is further exposed to this risk through subsidiaries operating in Israel and the U.S. as the Company’s functional currency is in Canadian dollars. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk. As such, the Company’s financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.

As of December 31, 2024 and December 31, 2023, the Company had foreign currency gain (loss) on translation of $(86,321) and $21,539, respectively. A 10% change in the exchange rates for the foreign currencies would affect the carrying amounts of net assets by approximately $40,125 and $97,678 as of December 31, 2024 and December 31, 2023, respectively.

Leases (Tables)

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Schedule of Lease Cost and Other Information


	As of December 31,
	2024			2023			2022
Lease cost
Operating lease cost	$	613		$	685		$	1,107
Short-term lease cost	—			—			—
Total lease cost	$	613		$	685		$	1,107

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	1,137		$	1,124		$	1,441
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	566			—			—

Weighted-average remaining lease term (years) – operating leases	3.6			3.6			4.3
Weighted-average discount rate – operating leases	7.71		%	7.62		%	7.39		%

Schedule of Future Minimum Lease Payments for Operating Leases

The following is a summary of the Company’s future minimum lease payments under operating leases for its premises due in future fiscal years:


	As of December 31, 2024
2025	$	1,146
2026	382
2027	229
2028	229
2029	96
Thereafter	319
Total lease payments	2,401
Less: imputed interest	(383)
Present value of lease liabilities	$	2,018

Business Combination - Schedule of Supplemental Proforma Results (Details) - Cronos GrowCo - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Net revenue	$ 125,089	$ 106,700
Gross profit	35,906	18,500
Operating expenses	103,031	101,995
Other income	66,202	49,441
Net income (loss) attributable to Cronos Group	$ 13,582	$ (44,256)

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2023 segment	Mar. 31, 2023 segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Impairment Of Intangible Asset, Finite-Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag			consolidated statements of net income (loss) and comprehensive income (loss)
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Net Derivative Asset (Liability) Gain (Loss), Statement Of Income, Extensible List, Not Disclosed Flag			consolidated statements of net income (loss)
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Net Derivative, Asset (Liability) Gain (Loss), Statement Of Other Comprehensive Income, Extensible List, Not Disclosed Flag			comprehensive income (loss)
Advertising costs \| $			$ 887	$ 1,382	$ 889
Number of reportable segments \| segment	1	2
Number of operating segments \| segment	1
Cronos Growing Company Inc.
Business Acquisition [Line Items]
Acquisition-related costs \| $			$ 701

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 36,586	$ (73,669)	$ (121,003)
Effective income tax rate	26.50%	26.50%	26.50%
Expected income tax expense (benefit)	$ 9,695	$ (19,522)	$ (32,066)
Non-taxable income (loss)	(11,138)	1,077	(2,140)
Non-deductible share-based compensation	143	525	1,198
Non-deductible expenses	741	459	836
Non-deductible transaction costs	(14)	351	1,625
Effect of provincial tax rate difference	(66)	(9)	(15)
Effect of tax rates outside of Canada	755	816	1,848
Effect of change in tax rates	11,533	4,601	11,041
Fair value gain (loss) on financial liabilities	(15)	23	(3,726)
Changes in valuation allowance	(19,367)	7,930	(10,466)
Capital gain on financial liabilities	0	106	66,193
Additional taxable income	3,746	0	0
Other	551	413	(153)
Income tax expense (benefit), net	$ (3,436)	$ (3,230)	$ 34,175

Share-based Compensation - Restricted Share Units Narrative (Details)	12 Months Ended
	Dec. 31, 2024
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Investments (Tables)

12 Months Ended

Dec. 31, 2024

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Investments

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2024		2023

Cronos GrowCo(i)	50%	$	—	$	19,488

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2024		2023		2022

Cronos GrowCo(i)	2,365		1,583		3,114

	$	2,365	$	1,583	$	3,114

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2024		2023		2022
Current assets	$	—	$	19,600	$	21,158
Non-current assets	—		99,227		104,227
Current liabilities	—		9,707		5,593
Non-current liabilities	—		64,814		73,779


	Year ended December 31,
	2024		2023		2022
Revenue	$	22,191	$	40,604	$	39,110
Gross profit	10,529		21,565		24,379
Net income	3,514		3,051		6,569

The following table summarizes the Company’s other investments activity:


	As of December 31, 2023		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2024
PharmaCann	$	25,650	$	—	$	(25,650)	$	—	$	—
Vitura	9,601		(6,206)		—		(582)		2,813
	$	35,251	$	(6,206)	$	(25,650)	$	(582)	$	2,813


	As of December 31, 2022		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2023
PharmaCann	$	49,000	$	—	$	(23,350)	$	—	$	25,650
Vitura	21,993		(12,096)		—		(296)		9,601
	$	70,993	$	(12,096)	$	(23,350)	$	(296)	$	35,251

Schedule of Variable Interest Entities

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2024		2023

Cronos GrowCo(i)	50%	$	—	$	19,488

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2024		2023		2022

Cronos GrowCo(i)	2,365		1,583		3,114

	$	2,365	$	1,583	$	3,114

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2024		2023		2022
Current assets	$	—	$	19,600	$	21,158
Non-current assets	—		99,227		104,227
Current liabilities	—		9,707		5,593
Non-current liabilities	—		64,814		73,779


	Year ended December 31,
	2024		2023		2022
Revenue	$	22,191	$	40,604	$	39,110
Gross profit	10,529		21,565		24,379
Net income	3,514		3,051		6,569

The following is a summary of the maximum exposure to loss from the Company’s investments in equity method investments as of December 31, 2023:


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss
Cronos GrowCo	50%	$	44,306	$	19,488


Balance as of December 31, 2023		$	44,306	$	19,488

The Company’s maximum exposure to loss is equal to the carrying amount of the investment.

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares	Dec. 31, 2023 $ / shares
Pre-emptive Rights \| Share price at valuation date (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.89	2.77
Pre-emptive Rights \| Subscription price (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.49	0.60
Pre-emptive Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0289	0.0399
Pre-emptive Rights \| Weighted Average \| Weighted average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	2 years	1 year 9 months
Top-up Rights \| Share price at valuation date (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.89	2.77
Top-up Rights \| Subscription price (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.48	0.58
Top-up Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0301	0.0476
Top-up Rights \| Weighted Average \| Weighted average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	9 months	7 months 6 days
Pre-Emptive Rights and Top-Up Rights \| Minimum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0289	0.0399
Pre-Emptive Rights and Top-Up Rights \| Minimum \| Weighted average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	9 months	6 months
Pre-Emptive Rights and Top-Up Rights \| Maximum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0301	0.0482
Pre-Emptive Rights and Top-Up Rights \| Maximum \| Weighted average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	2 years	1 year 9 months

Background, Basis of Presentation, and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Background, Basis of Presentation, and Summary of Significant Accounting Policies

(a)Background

Cronos Group Inc. (“Cronos” or the “Company”) is incorporated in the province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 4491 Concession Rd 12, Stayner, Ontario L0M 1S0. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.”

Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®.

(b)Basis of presentation

(c)Basis of consolidation

The accompanying consolidated financial statements include the accounts of the Company, and all entities in which the Company has a controlling voting interest or is the primary beneficiary of a variable interest as of and for the reporting periods. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. If an entity is not deemed to be a VIE, the Company consolidates the entity if the Company has a controlling voting interest. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. Investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not have control, are accounted for under the equity method of accounting. The Company consolidates the financial results of the following entities, which the Company controls but does not wholly own:

Subsidiaries

Jurisdiction of incorporation

Incorporation date

Ownership interest (iii)

Cronos Growing Company Inc.(i)

Canada

June 14, 2018

50%

Cronos Israel G.S. Cultivation Ltd.(ii)

Israel

February 4, 2018

70%

Cronos Israel G.S. Manufacturing Ltd.(ii)

Israel

September 4, 2018

90%

Cronos Israel G.S. Store Ltd.(ii)

Israel

June 28, 2018

90%

Cronos Israel G.S. Pharmacy Ltd.(ii)

Israel

February 15, 2018

90%

(i)Cronos Growing Company Inc. is referred to as “Cronos GrowCo.”

(ii)These Israeli entities are collectively referred to as “Cronos Israel.”

(iii)“Ownership interest” is defined as the proportionate share of net income to which the Company is entitled; equity interest may differ from ownership interest as described herein.

(d)Use of estimates

(e)Cash and cash equivalents and short-term investments

(f)Business combination

(g)Inventory

(h)Investments

Variable interest entities

Equity method investments

Other investments

(i)Property, plant and equipment

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

7 to 10 years

Furniture and fixtures

5 years

(j)Definite-lived intangible assets

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities
Know-how(ii)	Straight-line	10 years

(ii) Know-how was acquired as part of the Cronos GrowCo Transaction. See Note 2 “Business Combination” for further information.

(k)Accrued liabilities

Accrued liabilities consist of the following:


	As of December 31,
	2024		2023
Accrued payroll and related expenses	$	10,324	$	8,970
Accrued professional fees	1,537		2,525
Accrued taxes	11,831		11,695
Other accrued expenses	7,961		4,546
Total accrued liabilities	$	31,653	$	27,736

(l)Leases

not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company.

(m)Derivative liabilities

For financial instruments classified as derivatives that are not designated as hedging instruments or do not qualify for hedge accounting, changes in fair value are recorded in the consolidated statements of net income (loss) and comprehensive income (loss) each period. The Company does not enter into or hold derivative financial instruments for trading or speculative purposes. Derivative liabilities are initially recognized at fair value at the date on which the derivative contract was entered into. Any attributable transaction costs are recognized in net income (loss) as incurred. Subsequent to initial recognition, derivative liabilities are measured at fair value at each reporting date until settlement with the re-measurement gain or loss being recognized immediately in net income (loss) and comprehensive income (loss). See Note 10 “Derivative Liabilities” for more details on derivative liabilities consisting of the Altria Warrant, Pre-emptive Rights, and certain Top-up Rights.

(n)Capital stock

(o)Revenue recognition

The following table presents the Company’s revenue by major product category for continuing operations:


	Year ended December 31,
	2024		2023		2022
Cannabis flower	$	87,912	$	62,070	$	63,593
Cannabis extracts	29,168		24,569		22,522
Other	535		602		634
Net revenue	$	117,615	$	87,241	$	86,749

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

(p)Research and development

The Company has a research and development center in Canada that performs scientific research on the interaction of cannabinoids as well as strain development, growing conditions and extraction technology. In 2023, fermentation and production related research was performed to further strategic initiatives around rare cannabinoids. In addition, the Company has a collaboration and license agreement with Ginkgo (the “Ginkgo Collaboration Agreement”) to research, produce, and commercialize cultured cannabinoids. Technological feasibility is considered to be established once productivity targets or commercialization are achieved, at which point the exclusive license is recognized at cost less impairment charges. As of the acquisition date of each exclusive license, cost less impairment charges is equal to the fair value. See Note 8 “Goodwill and Intangible Assets, net” for more information on the Ginkgo Collaboration Arrangement. Research and development costs associated with these collective efforts are expensed as incurred as part of operating expenses in the Company’s consolidated statements of net income (loss) and comprehensive income (loss).

(q)Advertising costs

Advertising costs include costs to sell the Company’s products and are expensed as incurred through sales and marketing expenses in the consolidated statements of net income (loss) and comprehensive income (loss). Advertising costs were $887, $1,382 and $889 for the years ended December 31, 2024, 2023, and 2022, respectively.

(r)Share-based compensation

(s)Impairment of long-lived assets

(t)Assets held-for-sale and discontinued operations

(u)Impairment of goodwill and indefinite-lived intangible assets

Goodwill and indefinite-lived intangible assets are not amortized. Goodwill and indefinite-lived intangible assets are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value of the reporting unit has been reduced to less than its carrying amount in accordance with the provisions of ASC 350, Intangibles—Goodwill and Other. The Company performs an impairment test annually in the fourth quarter by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.

(v)Income taxes

(w)Foreign currency

(x)Segments

(y)Earnings (loss) per share

(z)Fair value measurements

The following are the three levels of inputs used to measure fair value:

•Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities.

•Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

•Level 3 – valuation techniques using the inputs for the asset or liability that are not based on observable market data.

The Company’s policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer.

(aa)Adoption of new accounting pronouncements

(ab)New accounting pronouncements not yet adopted

Financial Instruments - Credit Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk [Line Items]
Maximum exposure to credit risk	$ 904,101	$ 966,442
Accounts receivable, net	$ 15,462	13,984
Accounts receivable, threshold period past due, writeoff	120 days
Net revenue, before excise taxes	$ 161,821	120,270	$ 109,301
Cash and cash equivalents	858,805	669,291
Short-term investments	0	192,237
United States Segment
Concentration Risk [Line Items]
Current expected credit loss	$ 7	$ 3
One Major Customer \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%	37.00%
Two Major Customer \| Rest Of World Segment
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 78,627
Two Major Customer \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk \| Rest Of World Segment
Concentration Risk [Line Items]
Concentration risk, percentage	49.00%
Three Major Customers \| Rest Of World Segment
Concentration Risk [Line Items]
Net revenue, before excise taxes			$ 63,509
Three Major Customers \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk \| Rest Of World Segment
Concentration Risk [Line Items]
Concentration risk, percentage		66.00%	55.00%
Net revenue, before excise taxes		$ 79,503

Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 1,146
2026	382
2027	229
2028	229
2029	96
Thereafter	319
Total lease payments	2,401
Less: imputed interest	(383)
Present value of lease liabilities	$ 2,018

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The following table presents the major components comprising loss from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023, and 2022:


	Year ended December 31, 2023		Year ended December 31, 2022
Net revenue	$	1,029	$	5,155
Cost of sales	2,164		8,622
Inventory write-down(i)	839		—
Gross profit	(1,974)		(3,467)
Operating expenses
Sales and marketing	578		4,236
Research and development	32		250
General and administrative	668		3,504
Restructuring costs	523		1,788
Share-based compensation	13		107
Depreciation and amortization	13		58
Impairment loss on goodwill and indefinite-lived intangible assets	—		—
Impairment loss on long-lived assets(ii)	205		—
Total operating expenses	2,032		9,943
Interest income	10		23
Other, net(iii)	(118)		(169)
Total other loss	(108)		(146)
Loss before income taxes	(4,114)		(13,556)
Income tax expense (benefit)	—		—
Net loss from discontinued operations	(4,114)		(13,556)

(i)For the year ended December 31, 2023, Inventory write-down relates to the disposal of obsolete inventory as a result of the exit of the U.S. operations.

(iii)For the years ended December 31, 2023 and December 31, 2022, other, net related to loss on disposal of assets that were part of the U.S. operations.

The following tables present the Company’s discontinued operations revenue by major product category:



	2023		2022
Cannabis extracts	1,029		5,155
Net revenue	$	1,029	$	5,155



	2023			2022
Lease cost
Operating lease cost	$	213		$	1,102
Short-term lease cost	—			—
Total lease cost	$	213		$	1,102

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	525		$	1,050
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			443

Weighted-average remaining lease term (years) – operating leases	0.0			1.0
Weighted-average discount rate – operating leases	—		%	5.62		%

Schedule of Plan Information and Restructuring-Related Costs

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of December 31, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of December 31, 2021		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2024 and 2023:


	As of December 31, 2023		Expenses		Payments/Write-offs		As of December 31, 2024
Employee Termination Benefits	$	150	$	62	$	(212)	$	—

Other Restructuring Costs	—		568		(568)		—
Total	$	150	$	630	$	(780)	$	—


	As of December 31, 2022		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Derivative Liabilities

12 Months Ended

Dec. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liabilities

On March 8, 2019, the Company closed the previously announced investment in the Company (the “Altria Investment”) by Altria Group, Inc. (“Altria”), pursuant to a subscription agreement dated December 7, 2018. As of the closing date of the Altria Investment, the Altria Investment consisted of 149,831,154 common shares of the Company and one warrant of the Company (the “Altria Warrant”), issued to a wholly owned subsidiary of Altria. As of the closing date of the Altria Investment, Altria beneficially held an approximate 45% ownership interest in the Company (calculated on a non-diluted basis). On December 16, 2022, Altria notified the Company that it was irrevocably relinquishing all of its rights, title and interest in the Altria Warrant, effective immediately. As a result, the Company’s liability associated with the Altria Warrant was reduced to nil, with the change recorded to gain on revaluation of derivative liabilities for the year ended December 31, 2022.

Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the “Investor Rights Agreement”), the Company granted Altria certain rights, among others, summarized in this note.

The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable.

a.The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership with Ginkgo, the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Collaboration Agreement will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.

b.In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).

The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the 10 full days preceding such exercise by Altria; provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities on the Company’s consolidated balance sheet.

As of December 31, 2024, Altria beneficially held 156,573,537 of the Company’s common shares, an approximate 40.9% ownership interest in the Company (calculated on a non-diluted basis).

Reconciliations of the carrying amounts of the derivative liability are presented below:


	As of December 31, 2023		Loss (gain) on revaluation		Foreign exchange effect		As of December 31, 2024

Pre-emptive Rights	102		(49)		(13)		40
Top-up Rights	—		—		—		—
	$	102	$	(49)	$	(13)	$	40


	As of December 31, 2022		Gain on revaluation		Foreign exchange effect		As of December 31, 2023

Pre-emptive Rights	—		100		2		102
Top-up Rights	15		(15)		—		—
	$	15	$	85	$	2	$	102

Fluctuations in the expected life of the derivative instruments and the Company’s share price are primary drivers for the changes in the derivative valuations during each reporting period. As the period of time the derivative liability is expected to be outstanding decreases and the share price decreases, the fair value typically decreases for each related derivative instrument. Weighted-average expected life and share price are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments.

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:


	As of December 31, 2024
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.89	$2.89
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	2.89%	3.01%
Weighted average expected life (in years)(ii)	2.00	0.75
Expected annualized volatility(iii)	49%	48%
Expected dividend yield	—%	—%


	As of December 31, 2023
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.77	$2.77
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	3.99%	4.76%
Weighted average expected life (in years)(ii)	1.75	0.60
Expected annualized volatility(iii)	60%	58%
Expected dividend yield	—%	—%

(i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of December 31, 2024 and December 31, 2023, the risk-free interest rate uses a range of approximately 2.89% to 3.01% and 3.99% to 4.82%, respectively, for the Pre-emptive Rights and Top-up Rights.

(ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-

up Rights are linked. As of December 31, 2024 and December 31, 2023, the expected life uses a range of approximately 0.75 years to 2.00 years and 0.50 years to 1.75 years, respectively.

(iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Share-based Compensation

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-based Compensation

(a)Share-based award plans

The Company has granted stock options, RSUs and DSUs to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan.

The following table summarizes the total share-based compensation associated with the Company’s stock options and RSUs:


	Year ended December 31,
	2024		2023		2022
Stock options	$	134	$	1,175	$	6,778
RSUs	8,566		7,581		7,633
Liability-classified awards(i)	—		—		597
Total share-based compensation	$	8,700	$	8,756	$	15,008

(i)Represents share-based compensation awards conditionally approved for grant to one of the Company’s former executives for a fixed monetary value, but a variable number of shares. These awards were liability-classified until the number of shares was determined.

(b)Stock options

On June 28, 2018, the shareholders of the Company approved the 2018 Stock Option Plan, which replaced the 2015 Stock Option Plan. The 2018 Stock Option Plan terminated the Company’s ability to grant equity under the 2015 Stock Option Plan. As of June 25, 2020, the date on which the 2020 Omnibus Plan was approved by the shareholders of the Company, no further awards will be granted under the 2018 Stock Option Plan; however, shares may be purchased via option exercise by the holders of any outstanding options previously issued under the 2018 Stock Option Plan.

On March 29, 2020, the Board adopted the 2020 Omnibus Plan, which was approved by the shareholders of the Company at the annual and special meeting of shareholders held on June 25, 2020. The 2020 Omnibus Plan provides for grants of stock options, share appreciation rights, restricted shares, RSUs and other share-based or cash-based awards, which are subject to terms as determined by the Compensation Committee of the Board (the “Compensation Committee”), and awards may be granted to eligible employees, non-employee directors and consultants. The 2020 Omnibus Plan terminated the Company’s ability to grant equity awards under the 2018 Stock Option Plan and RSUs under the Employment Inducement Award Plan.

Options represent the right to purchase Company common shares on the date of exercise at a stated exercise price. The exercise price of an option generally must be at least equal to the fair market value of the Company common shares on the date of grant. Vesting conditions for grants of options are determined by the Compensation Committee. The typical vesting for stock option grants is quarterly vesting over three to five years. The maximum term of options granted under the 2020 Omnibus Plan is seven years. Participants under the 2020 Omnibus Plan are eligible to be granted options to purchase shares at an exercise price established upon approval of the grant by the Compensation Committee. When options are granted, the exercise price is, with respect to a particular date, the closing price as reported by the TSX or the Nasdaq and, if the shares are not traded on the TSX or the Nasdaq, any other stock exchange on which the Company’s common shares are traded (as selected by the Compensation Committee in good faith taking into account applicable legal and tax requirements) on the immediately preceding trading day (the “Fair Market Value”). The 2020 Omnibus Plan does not authorize grants of options with an exercise price below the Fair Market Value.

The following is a summary of the changes in options:


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Issuance of options	—		—

Cancellation, forfeiture and expiry of options	19.05		(1,385,937)
Balance as of December 31, 2024	$	5.63	717,264	3.65
Exercisable as of December 31, 2024	$	6.29	554,361	3.23


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of December 31, 2022	$	10.57	5,350,600	0.73
Issuance of options	2.96		188,317

Cancellation, forfeiture and expiry of options	7.75		(3,435,716)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Exercisable as of December 31, 2023	$	15.89	1,864,732	1.29

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.

For the year ended December 31, 2023, the fair value per option at grant date was C$2.07. There were no options granted in 2024. The fair value of the options issued during 2023 was determined using the Black-Scholes option pricing model, using the following inputs:


									2023
Share price at grant date (per share)									C$2.96
Exercise price (per option)									C$2.96
Risk-free interest rate(i)									3.22%
Expected life of options (in years)(i)									7
Expected annualized volatility(i)									73%
Expected dividend yield									—
Weighted average Black-Scholes value at grant date (per option)									C$2.07
Forfeiture rate									—

(i)The expected life of the awards represents the period of time options are expected to be outstanding and is estimated considering vesting terms and employees’ and non-employees’ historical exercise and, where relevant, post-vesting employment termination behavior. Volatility was estimated by using the historical volatility of the Company’s share price, adjusted for the Company’s expectation of volatility going forward. The risk-free interest rate was based on the Bank of Canada government bonds with a remaining term equal to the expected life of the options at the grant date.

The following table summarizes stock options outstanding:


	Options outstanding as of December 31,
	2024	2023	2022
2020 Omnibus Plan	702,264	702,264	2,788,947
2018 Stock Option Plan	15,000	1,400,937	1,422,069
2015 Stock Option Plan	—	—	1,139,584
Total stock options outstanding	717,264	2,103,201	5,350,600

(c)Restricted share units

RSUs are granted under the 2020 Omnibus Plan. RSUs represent an equivalent amount of Company common shares on the date of issuance at fair value. Fair value is determined using the closing price of the trading day immediately preceding the date of grant. RSUs issued under the 2020 Omnibus Plan typically vest over a three-year period following the grant date and have no performance requirements.

The following is a summary of the changes in RSUs:


	Weighted average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2023	$	3.77	7,381,541
Granted(i)	2.92		2,987,147
Vested and issued	3.49		(1,726,230)
Cancellation and forfeitures	3.18		(260,245)
Balance as of December 31, 2024	$	3.50	8,382,213


	Weighted average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2022	$	4.63	5,725,470
Granted(i)	2.64		3,292,586
Vested and issued	5.00		(1,041,097)
Cancellation and forfeitures	3.60		(595,418)
Balance as of December 31, 2023	$	3.77	7,381,541

(i)RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three or five year “cliff-period.” All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

(ii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

(d)Deferred share units

On August 10, 2019, the Company established the DSU Plan pursuant to which its non-executive directors receive DSUs for Board services. The DSU Plan is designed to promote a greater alignment of long-term interests between non-executive directors and shareholders. The number of DSUs granted under the DSU Plan (including fractional DSUs) is determined by dividing the amount of remuneration payable by the closing price as reported by the TSX for awards made prior to 2022 and as reported by Nasdaq for awards made in 2022 and subsequent years on the trading day immediately preceding the date of grant. DSUs are payable at the time a non-executive director ceases to hold the office of director for any reason and are settled by a lump-sum cash payment, in accordance with the terms of the DSU Plan, based on the fair value of the DSUs at such time. The fair value of the cash payout is determined by multiplying the number of DSUs vested at the payout date by the closing price as reported by the TSX for awards made prior to 2022 and as reported by Nasdaq for awards made in 2022 and subsequent years on the trading day immediately preceding the payout date. The fair value of the cash payout is determined at each reporting date based on the fair value of the Company’s common shares at the reporting date and is recorded within other liabilities.

The following is a summary of the changes in DSUs:


	Financial liability		Number of DSUs
Balance as of December 31, 2023	$	1,092	521,679
Granting and vesting of DSUs	450		193,965
Liabilities settled	(359)		(155,383)
Gain on revaluation	(54)		—
Balance as of December 31, 2024	$	1,129	560,261


	Financial liability		Number of DSUs
Balance as of December 31, 2022	$	674	265,732
Granting and vesting of DSUs	450		255,947

Loss on revaluation	(32)		—
Balance as of December 31, 2023	$	1,092	521,679

(e)Liability-classified awards

During the year ended December 31, 2022, the Compensation Committee conditionally approved the grant to one of the Company’s former executives of share-based compensation awards for a fixed monetary amount, but a variable number of common shares. These awards were liability-classified until the number of common shares was determined prior to year-end 2022. During the years ended December 31, 2024 and 2023, there was no liability-classified award activity.

Loans Receivable, net - Narrative (Details) ₪ in Thousands		1 Months Ended	6 Months Ended		12 Months Ended				58 Months Ended
Loans Receivable, net - Narrative (Details) ₪ in Thousands	Jun. 20, 2024 CAD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Dec. 31, 2024 ILS (₪)	Dec. 31, 2023 ILS (₪)	Sep. 30, 2022	Aug. 31, 2021 CAD ($)	Aug. 23, 2019 CAD ($)	Jun. 28, 2019 USD ($)	Jun. 28, 2019 CAD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Draw downs					$ 8,759,000	$ 0		$ 0
Proceeds from loans receivable					5,252,000	16,831,000		5,246,000
Gain on revaluation of loan receivable					11,804,000	0		$ 0
GrowCo Credit Facility(ii) \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Face amount														$ 105,000,000	$ 100,000,000
Face amount increase		$ 70,000,000
Financing receivable term		10 years	10 years	10 years					10 years	10 years
Draw downs	$ 12,000,000		$ 84,833,000	$ 116,000,000		78,532,000	$ 104,000,000
Proceeds from loans receivable			2,447,000	3,333,000					$ 10,848,000	$ 14,833,000
Interest received			$ 2,835,000	$ 3,862,000					$ 17,832,000	$ 24,384,000
Mucci Promissory Note \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Face amount																$ 11,393,000	$ 16,350,000
Interest received						897,000	1,187,000
Stated interest rate																3.95%	3.95%
Loans receivable, basis spread on variable rate													1.25%
Proceeds from repayment on loan outstanding principal						425,000	$ 563,000
Cannasoul Collaboration Loan \| Loans Receivable \| Variable Interest Entity, Not Primary Beneficiary \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Cannasoul Lab Services Ltd.
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received					$ 2,272,000	$ 2,294,000					₪ 8,297	₪ 8,297

Investments - Schedule of Variable Interest Entities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Other Net Assets (Liabilities)		$ 44,306
Maximum Exposure to Loss		$ 19,488
Cronos GrowCo
Variable Interest Entity [Line Items]
Ownership interest	50.00%	50.00%
Cronos GrowCo \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Other Net Assets (Liabilities)		$ 44,306
Maximum Exposure to Loss		$ 19,488

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Restructuring - Schedule of Restructuring Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Expenses	$ 630	$ 1,524	$ 3,545
Realignment
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	150	424
Expenses	630	1,524
Payments/Write-offs	(780)	(1,798)
Accrual, ending balance	0	150	424
Employee Termination Benefits \| Realignment
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	150	403
Expenses	62	1,371
Payments/Write-offs	(212)	(1,624)
Accrual, ending balance	0	150	403
Other Restructuring Costs \| Realignment
Restructuring Reserve [Roll Forward]
Accrual, beginning balance	0	21
Expenses	568	153
Payments/Write-offs	(568)	(174)
Accrual, ending balance	$ 0	$ 0	$ 21

Loans Receivable, net - Schedule of Loan Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable	$ 618	$ 5,541
Total long-term portion of loans receivable	15,526	69,036
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Current portion of Mucci Promissory Note accrued interest	618	507
Total current portion of loans receivable	618	5,541
Add: Long-term portion of accrued interest	326	248
Total long-term portion of loans receivable	15,526	69,036
Total loans receivable	16,144	74,577
GrowCo Credit Facility(ii) \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	0	5,034
Long term portion of loans receivable, before accrued interest	0	53,638
Mucci Promissory Note \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	13,464	13,379
Cannasoul Collaboration Loan \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	$ 1,736	$ 1,771

Segment Information - Schedule of Revenue from External Customers by Geographic Areas and Cash and Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 117,615	$ 87,241	$ 86,749
Total cash and cash equivalents and short-term investments	858,805	861,528
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	82,437	64,702	56,233
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	28,368	21,134	30,516
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	6,810	1,405	0
Cannabis flower
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	87,912	62,070	63,593
Cannabis extracts
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	29,168	24,569	22,522
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 535	$ 602	$ 634

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

Segment reporting is prepared on the same basis that the CODM manages the business, makes operating decisions and assesses the Company’s performance. The CODM is the Company’s Chief Executive Officer. The Company operates as a single segment with the purpose of providing high-quality cannabis products to adult-use, wholesale, and medical market customers globally. The consolidated results are regularly reviewed by the CODM to assess the performance of the Company’s single segment operations and make decisions regarding the allocation of resources. The CODM reviews adjusted earnings (loss) before interest, tax, depreciation and amortization (“Adjusted EBITDA”) as the measure of segment profit or loss to evaluate performance of and allocate resources for its reportable segment. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, and non-cash items and items that do not reflect management’s assessment of ongoing business performance. The CODM believes Adjusted EBITDA provides the most useful insight into underlying business trends and results and provides a more meaningful comparison of period-over-period results. In addition, certain significant expenses are regularly reviewed by the CODM and considered for business decisions and allocation of resources; these significant expenses include: sales and marketing, research and development, general and administrative, depreciation and amortization, and share-based compensation expense, which are presented within operating expenses on the Company’s consolidated statements of net income (loss) and comprehensive income (loss). Furthermore, the CODM regularly reviews total cash and short-term investments to aid in capital allocation decisions.

The tables below set forth consolidated Adjusted EBITDA and significant expenses for our single segment:


	Year ended December 31,
	2024		2023		2022
Adjusted EBITDA	$	(34,942)	$	(63,746)	$	(80,608)

Significant expenses:
Sales and marketing	21,603		22,701		18,046
Research and development	4,229		5,843		13,131
General and administrative	46,514		49,475		67,674
Share-based compensation	8,700		8,756		15,008
Depreciation and amortization	3,701		5,044		5,967
Total significant expenses	84,747		91,819		119,826
Restructuring costs	630		1,524		3,545
Impairment loss on long-lived assets	16,350		3,366		3,493
Total operating expense	$	101,727	$	96,709	$	126,864

The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated:


(in thousands of U.S. dollars)	For the year ended December 31, 2024
	Continuing Operations		Discontinued Operations		Total
Net income	$	40,022	$	—	$	40,022
Interest income, net	(52,019)		—		(52,019)
Income tax benefit	(3,436)		—		(3,436)
Depreciation and amortization	9,336		—		9,336
EBITDA	(6,097)		—		(6,097)
Share of income from equity method investments	(2,365)		—		(2,365)
Impairment loss on long-lived assets(i)	16,350		—		16,350
Revaluation gain on loan receivable(ii)	(11,804)		—		(11,804)
Gain on revaluation of equity method investment(iii)	(32,469)		—		(32,469)
Gain on revaluation of derivative liabilities(iv)	(49)		—		(49)
Loss on revaluation of financial instruments(v)	6,248		—		6,248
Impairment loss on other investments(vi)	25,650		—		25,650
Foreign currency transaction gain	(57,859)		—		(57,859)
Transaction costs(vii)	701		—		701
Loss on held-for-sale assets(viii)	11,202		—		11,202
Other, net(ix)	350		—		350
Restructuring costs(x)	630		—		630
Share-based compensation(xi)	8,700		—		8,700
Financial statement review costs(xii)	(1)		—		(1)

Inventory step-up recorded to cost of sales(xiv)	5,284		—		5,284
Israel Ministry of Economy and Industry dumping inquiry expense(xv)	587		$	—	587
Adjusted EBITDA	$	(34,942)	$	—	$	(34,942)


(in thousands of U.S. dollars)	For the year ended December 31, 2023
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(70,439)	$	(4,114)	$	(74,553)
Interest income, net	(51,235)		(10)		(51,245)
Income tax benefit	(3,230)		—		(3,230)
Depreciation and amortization	7,866		244		8,110
EBITDA	(117,038)		(3,880)		(120,918)
Share of income from equity method investments	(1,583)		—		(1,583)
Impairment loss on long-lived assets(i)	3,366		205		3,571
Loss on revaluation of derivative liabilities(iv)	85		—		85
Loss on revaluation of financial instruments(v)	12,042		—		12,042
Impairment loss on other investments(vi)	23,350		—		23,350
Foreign currency transaction loss	7,324		—		7,324
Other, net(ix)	(1,114)		118		(996)
Restructuring costs(x)	1,524		523		2,047
Share-based compensation(xi)	8,756		13		8,769
Financial statement review costs(xii)	919		—		919
Inventory write-down(xiii)	805		839		1,644
Adjusted EBITDA	$	(61,564)	$	(2,182)	$	(63,746)


(in thousands of U.S. dollars)	For the year ended December 31, 2022
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(155,178)	$	(13,556)	$	(168,734)
Interest income, net	(22,514)		(23)		(22,537)
Income tax expense	34,175		—		34,175
Depreciation and amortization	11,924		1,198		13,122
EBITDA	(131,593)		(12,381)		(143,974)
Share of income from equity method investments	(3,114)		—		(3,114)
Impairment loss on long-lived assets(i)	3,493		—		3,493
Gain on revaluation of derivative liabilities(iv)	(14,060)		—		(14,060)
Gain on revaluation of financial instruments(v)	(14,739)		—		(14,739)
Impairment loss on other investments(vi)	61,392		—		61,392
Foreign currency transaction loss	2,286		—		2,286
Other, net(ix)	324		169		493
Restructuring costs(x)	3,545		1,788		5,333
Share-based compensation(xi)	15,008		107		15,115
Financial statement review costs(xii)	7,167		—		7,167
Adjusted EBITDA	$	(70,291)	$	(10,317)	$	(80,608)

(ii)For the year ended December 31, 2024, a revaluation gain on loan receivable was recognized as a result of the Cronos GrowCo Transaction on July 1, 2024.

(iii)For the year ended December 31, 2024, a gain on revaluation of equity method investment was recognized as a result of the Cronos GrowCo Transaction on July 1, 2024.

(ix)For the years ended December 31, 2024, 2023 and 2022, other, net primarily related to (gain) loss on disposal of assets.

The following table presents the Company’s revenue by major product category for our single segment:


	Year ended December 31,
	2024		2023		2022
Cannabis flower	$	87,912	$	62,070	$	63,593
Cannabis extracts	29,168		24,569		22,522
Other	535		602		634
Net revenue	$	117,615	$	87,241	$	86,749

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2024		2023		2022
Canada	$	82,437	$	64,702	$	56,233
Israel	28,368		21,134		30,516

Other countries	6,810		1,405		—
Net revenue	$	117,615	$	87,241	$	86,749

The table below sets forth total cash and cash equivalents and short-term investments for our single segment:


	As of December 31,
	2024		2023
Total cash and cash equivalents and short-term investments	$	858,805	$	861,528

Property, plant and equipment, net were physically located in the following geographic regions:


	As of December 31,
	2024		2023
Canada	$	117,329	$	41,513

Israel	15,860		17,985
Total	$	133,189	$	59,498

Intangibles, net were physically located in the following geographic regions:


	As of December 31,
	2024		2023
Canada	$	10,887	$	20,531

Israel	370		547
Total	$	11,257	$	21,078

For additions to our property, plant and equipment, net and intangibles, net in the years ended December 31, 2024, 2023 and 2022, please see the consolidated statements of cash flows.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Property, Plant and Equipment, net

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2024		2023
Cost
Land		$	6,389	$	2,764
Building and leasehold improvements		192,059		168,498
Machinery and equipment		36,741		21,322
Furniture and fixtures		2,687		3,385
Construction in progress		28,710		3,269
Less: accumulated depreciation		(29,798)		(30,707)
Less: accumulated impairment charges		(103,599)		(109,063)
Property, Plant and Equipment, net		$	133,189	$	59,468

For the years ended December 31, 2024, 2023 and 2022, depreciation expense on property, plant and equipment was $5,506, $3,913 and $8,667, respectively, and was included in cost of sales as well as depreciation and amortization in operating expenses on the consolidated statements of net income (loss) and comprehensive income (loss).

The following table presents details of the property, plant and equipment acquired on July 1, 2024, as a result of the Cronos GrowCo Transaction by major category:


	Fair value at date of Cronos GrowCo Transaction
Land	$	4,557
Building and leasehold improvements	49,356
Machinery and equipment	21,603
Furniture and fixtures	580
Construction in progress	11,534
Total	$	87,630

See Note 2 “Business Combination” for more information regarding the Cronos GrowCo Transaction.

Impairment of Long-lived Assets

During the first quarter of 2024, the Company ceased operations at the Cronos Fermentation Facility and performed an assessment under ASC 360 of the recoverability of the carrying value of the assets of Thanos Holdings Ltd., known as Cronos Fermentation (“Cronos Fermentation”), and determined the carrying value of the assets was not fully recoverable. The fair value was estimated using a combination of the market and income approaches. As a result of this analysis, an impairment loss on long-lived assets of $1,631 was recorded to the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2024.

During the third quarter of 2023, as a result of the Company’s decision to wind down the operations at Cronos Fermentation, the Company performed an assessment of the recovery of the carrying value of the Canada asset group and determined the carrying value of the asset group was recoverable.

During the first quarter of 2022, the Company recognized an impairment charge of $1,507 related to leasehold improvements and other office equipment that it planned to include in any potential sublease agreement of the Company’s corporate headquarters in Toronto, Ontario, Canada. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. The impairment charge was recognized as impairment loss on long-lived assets on the consolidated statements of net income (loss) and comprehensive income (loss).

Held-for-sale Assessments

As of December 31, 2024, the Company classified certain assets as held for sale, in accordance with ASC 360, Property, Plant and Equipment. These assets primarily include buildings and machinery and equipment related to production at Cronos Fermentation. The decision to classify these assets as held-for-sale reflects management’s determination to sell the assets. The assets are measured at their fair value less costs to sell of $8,112. See Note 18 “Restructuring”

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Operating lease, extension term	10 years
Operating lease, impairment loss			$ 1,986
General and Administrative Expense
Lessee, Lease, Description [Line Items]
Depreciation expense on right-of-use assets	$ 486	$ 455	$ 839
Land
Lessee, Lease, Description [Line Items]
Operating lease, term	15 years
Minimum \| Office Premises and Equipment
Lessee, Lease, Description [Line Items]
Operating lease, term	19 months
Maximum \| Office Premises and Equipment
Lessee, Lease, Description [Line Items]
Operating lease, term	6 years

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Property, Plant & Equipment, Useful Lives (Details)	Dec. 31, 2024
Building and leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	15 years
Building and leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	20 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	7 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	10 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	5 years

Goodwill and Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	$ 14,258	$ 3,366	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 117,615	$ 87,241	$ 86,749
Canada
Segment Reporting Information [Line Items]
Revenue	82,437	64,702	56,233
Israel
Segment Reporting Information [Line Items]
Revenue	28,368	21,134	30,516
Other countries
Segment Reporting Information [Line Items]
Revenue	6,810	1,405	0
Cannabis flower
Segment Reporting Information [Line Items]
Revenue	87,912	62,070	63,593
Cannabis extracts
Segment Reporting Information [Line Items]
Revenue	29,168	24,569	22,522
Other
Segment Reporting Information [Line Items]
Revenue	$ 535	$ 602	$ 634

- Definition

+ References

+ Details

Loans Receivable, net

12 Months Ended

Dec. 31, 2024

Receivables [Abstract]

Loans Receivable, net

Loans receivable, net consists of the following:


	As of December 31,
	2024		2023


GrowCo Credit Facility(i)	$	—	$	5,034
Add: Current portion of Mucci Promissory Note accrued interest	618		507
Total current portion of loans receivable	618		5,541
GrowCo Credit Facility(i)	—		53,638
Mucci Promissory Note	13,464		13,379
Cannasoul Collaboration Loan	1,736		1,771
Add: Long-term portion of accrued interest	326		248
Total long-term portion of loans receivable	15,526		69,036
Total loans receivable(i)	$	16,144	$	74,577

(i) The Company obtained control of Cronos GrowCo on July 1, 2024, and, as a result, the loans receivable from Cronos GrowCo are now accounted for as intercompany transactions and eliminated upon consolidation from the business combination date onwards.

Cronos GrowCo Credit Facility

On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Credit Facility”). The GrowCo Credit Facility is secured by substantially all present and after-acquired personal and real property of Cronos GrowCo. In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$105,000.

In June 2024, the GrowCo Credit Facility was amended to increase the aggregate principal amount available by C$70,000 by providing a second secured non-revolving credit facility (“Term Loan B”). The funds from Term Loan B will be used to expand Cronos GrowCo’s purpose-built cannabis facility and Term Loan B will mature 10 years after the commencement of sales from the Phase 2 Expansion Area. Principal will be repaid under Term Loan B on a quarterly basis after the commencement of sales from the Phase 2 Expansion Area. Interest on Term Loan B is payable on a quarterly basis until maturity beginning after the first borrowing under Term Loan B. Prior to July 1, 2024, only C$12,000 of the C$70,000 increased principal availability could be drawn, which Cronos GrowCo drew in full on June 20, 2024.

As of June 30, 2024 and December 31, 2023, Cronos GrowCo had drawn C$116,000 and C$104,000 ($84,833 and $78,532, respectively), respectively from the GrowCo Credit Facility. For the six months ended June 30, 2024, Cronos GrowCo repaid C$3,333 ($2,447) in principal and C$3,862 ($2,835) in interest related to the GrowCo Credit Facility. As of June 30, 2024, Cronos GrowCo had repaid an aggregate C$14,833 ($10,848) and C$24,384 ($17,832) in principal and interest, respectively, under the terms of the GrowCo Credit Facility.

As a result of the Cronos GrowCo Transaction on July 1, 2024, the existing loans receivable under the GrowCo Credit Facility were remeasured at their fair value and effectively settled. We recorded a gain of $11,804 to revaluation gain on loans receivable on the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2024, from remeasuring our outstanding loans receivable with Cronos GrowCo. See Note 2 “Business Combination” for further information regarding the Cronos GrowCo Transaction.

Mucci Promissory Note

On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$16,350 (approximately $11,393) with 2645485 Ontario Inc. (“Mucci”). The Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023. On June 20, 2024, the Mucci Promissory Note was amended and restated. As a result, interest accrued on the Mucci Promissory Note between July 1, 2023 and July 1, 2024 was capitalized as part of the principal balance. As of July 1, 2024, interest is accrued and to be paid in cash beginning on July 1, 2025.

Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. Prior to 2023, there were no repayments of principal or interest on the Mucci Promissory Note. For the year ended December 31, 2023, Mucci repaid C$563 ($425) in principal and C$1,187 ($897) in interest related to the Mucci Promissory Note which had accrued between July 1, 2022 and July 1, 2023.

Cannasoul Collaboration Loan

As of both December 31, 2024 and 2023, CLS has received ILS 8,297 (approximately $2,272 and $2,294, respectively), from the Cannasoul Collaboration Loan. See Note 5 “Investments” for further information regarding the Cannasoul Collaboration Loan.

Expected credit loss allowances on the Company’s long-term financial assets were comprised of the following items:


	As of December 31, 2023		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2024
GrowCo Credit Facility(ii)	$	11,176	$	(10,794)	$	(382)	$	—

Mucci Promissory Note	89		6		(7)		88
Cannasoul Collaboration Loan	524		16		(5)		535
	$	11,789	$	(10,772)	$	(394)	$	623


	As of December 31, 2022		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2023
GrowCo Credit Facility	$	12,455	$	(1,542)	$	263	$	11,176

Mucci Promissory Note	89		(2)		2		89
Cannasoul Collaboration Loan	522		16		(14)		524
	$	13,066	$	(1,528)	$	251	$	11,789

(i)During the years ended December 31, 2024 and 2023, $1,032 and $(1,528), respectively, were recorded to general and administrative expenses on the consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses. During the year ended December 31, 2024, $11,804 was recorded as a gain on revaluation of loans receivable on the consolidated statements of net income (loss) and comprehensive income (loss) from remeasuring our outstanding loans receivable with Cronos GrowCo as a result of the Cronos GrowCo Transaction.

(ii)The Company obtained control of Cronos GrowCo on July 1, 2024, and, as a result, the loans receivable from Cronos GrowCo are now accounted for as intercompany transactions and eliminated upon consolidation from the business combination date onwards.

Inventory, net - Schedule of Inventory, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 5,400	$ 4,795
Work-in-progress	14,350	10,593
Finished goods	13,248	14,819
Supplies and consumables	151	288
Total	$ 33,149	$ 30,495

Segment Information - Schedule of Adjusted EBITDA and Significant Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Significant expenses:
Sales and marketing	$ 21,603	$ 22,701	$ 18,046
Research and development	4,229	5,843	13,131
General and administrative	46,514	49,475	67,674
Share-based compensation	8,700	8,756	15,008
Depreciation and amortization	3,701	5,044	5,967
Restructuring costs	630	1,524	3,545
Impairment loss on long-lived assets	16,350	3,366	3,493
Total operating expenses	101,727	96,709	126,864
Reportable Segment
Segment Reporting Information [Line Items]
Adjusted EBITDA	(34,942)	(63,746)	(80,608)
Significant expenses:
Sales and marketing	21,603	22,701	18,046
Research and development	4,229	5,843	13,131
General and administrative	46,514	49,475	67,674
Share-based compensation	8,700	8,756	15,008
Depreciation and amortization	3,701	5,044	5,967
Total significant expenses	84,747	91,819	119,826
Restructuring costs	630	1,524	3,545
Impairment loss on long-lived assets	16,350	3,366	3,493
Total operating expenses	$ 101,727	$ 96,709	$ 126,864

Restructuring

12 Months Ended

Dec. 31, 2024

Restructuring and Related Activities [Abstract]

Restructuring

In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, under which the Company is maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the Company’s products. In the third quarter of 2023, the Board approved revisions to the Realignment to wind-down operations at Cronos Fermentation, list the Cronos Fermentation Facility for sale, and implement additional organization-wide cost reductions as the Company continues its Realignment initiatives. The Realignment initiatives were intended to position the Company to drive profitable and sustainable growth over time.

On November 26, 2023, the Company entered into an agreement with Future Farmco Canada Inc. for the sale and leaseback of the Peace Naturals Campus. This agreement was subsequently terminated pursuant to its terms during the second quarter of 2024. The Company plans to continue and expand operations at the Peace Naturals Campus.

During the first quarter of 2024, the Company ceased operations at the Cronos Fermentation Facility, performed an assessment under ASC 360 of the recoverability of the carrying value of the Cronos Fermentation assets, and determined the carrying value of the assets was not fully recoverable. The fair value was estimated using a combination of the market and income approaches. As a result of this analysis, an impairment loss on long-lived assets of $1,631 was recorded to the consolidated statements of net income (loss) and comprehensive income (loss) in the year ended December 31, 2024. In addition, the Cronos Fermentation assets were classified as held-for-sale in the first quarter of 2024 at a fair value less costs to sell of $19,398 and continue to be classified as held-for-sale as of December 31, 2024. During the third quarter of 2024, the Company adjusted its sales strategy for the Cronos Fermentation assets to market the assets to a broader buyer pool, which resulted in the recognition of a loss on held-for-sale assets of $10,422 on the consolidated statements of net income (loss) and comprehensive income (loss) in year ended December 31, 2024. During the fourth quarter of 2024, the Company recorded an additional loss on these held-for-sale assets of $345.

During the year ended December 31, 2024, the Company incurred $630 of restructuring costs in its continuing operations in connection with the Realignment. During the year ended December 31, 2023, the Company recognized $1,524 of restructuring costs in continuing operations in connection with the Realignment. Charges related thereto include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. During the year ended December 31, 2023, as a result of the decision to wind down operations at Cronos Fermentation, the Company recognized an inventory write-down of $805 related to certain obsolete raw materials. Restructuring costs and inventory write-downs incurred in the Company’s discontinued operations during the years ended December 31, 2024 and 2023 is presented in Note 3 “Discontinued Operations”.

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2024 and 2023:


	As of December 31, 2023		Expenses		Payments/Write-offs		As of December 31, 2024
Employee Termination Benefits	$	150	$	62	$	(212)	$	—

Other Restructuring Costs	—		568		(568)		—
Total	$	150	$	630	$	(780)	$	—


	As of December 31, 2022		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150

Financial Instruments - Foreign Currency Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Foreign exchange gain (loss) on translation	$ (86,321)	$ 21,539	$ (50,616)
Impact of ten percent change in exchange rate	$ 40,125	$ 97,678

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 48,883	$ 43,933
Accumulated amortization	(12,107)	(9,659)
Accumulated impairment charges	(27,019)	(14,696)
Net	9,757	19,578
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Cost	113,025	108,075
Accumulated amortization	(12,107)	(9,659)
Accumulated impairment charges	(89,661)	(77,338)	$ (73,650)	$ (74,308)
Total intangible assets	11,257	21,078
Lord Jones brand
Indefinite-lived Intangible Assets [Line Items]
Cost	64,000	64,000
Accumulated impairment charges	(62,500)	(62,500)	(62,500)	(62,500)
Indefinite-Lived Intangible Assets (Excluding Goodwill), Total	1,500	1,500
Trademarks
Indefinite-lived Intangible Assets [Line Items]
Cost	142	142
Accumulated impairment charges	(142)	(142)	(142)	(142)
Indefinite-Lived Intangible Assets (Excluding Goodwill), Total	0	0
Software
Finite-Lived Intangible Assets [Line Items]
Cost	6,988	6,860
Accumulated amortization	(4,646)	(3,508)
Accumulated impairment charges	(72)	(78)	(76)	(4)
Net	2,270	3,274
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(4,646)	(3,508)
Health Canada licenses
Finite-Lived Intangible Assets [Line Items]
Cost	7,810	8,463
Accumulated amortization	(1,673)	(1,813)
Accumulated impairment charges	(6,137)	(6,650)	(6,498)	(6,910)
Net	0	0
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(1,673)	(1,813)
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Cost	26,139	28,326
Accumulated amortization	(5,329)	(4,276)
Accumulated impairment charges	(20,810)	(7,968)	$ (4,434)	$ (4,752)
Net	0	16,082
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(5,329)	(4,276)
Israeli codes
Finite-Lived Intangible Assets [Line Items]
Cost	281	284
Accumulated amortization	(76)	(62)
Accumulated impairment charges	0
Net	205	222
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(76)	$ (62)
Know-How
Finite-Lived Intangible Assets [Line Items]
Cost	7,665
Accumulated amortization	(383)
Net	7,282
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	$ (383)

Share-based Compensation - Schedule of Stock Options Outstanding (Details) - shares	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	717,264	2,103,201	5,350,600
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	702,264	702,264	2,788,947
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	15,000	1,400,937	1,422,069
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	0	0	1,139,584

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Investments - Narrative (Details) $ / shares in Units, ₪ in Thousands, $ in Thousands		3 Months Ended						12 Months Ended
	Jun. 14, 2021 USD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 12, 2025 shares	Dec. 31, 2024 ILS (₪)	Feb. 28, 2022	Oct. 12, 2021
Variable Interest Entity [Line Items]
Gain on revaluation of equity method investment								$ 32,469	$ 0	$ 0
Sale of stock, price per share (in dollars per share) \| $ / shares	$ 0.0001
Percentage of ownership after transaction	10.50%
Payments to acquire other investments	$ 110,392
Impairment charges								25,650	23,350	61,392
Loss on revaluation of other investments								6,248	12,042	$ (14,739)
Other investments				$ 35,251				2,813	$ 35,251
Cronos GrowCo
Variable Interest Entity [Line Items]
Gain on revaluation of equity method investment								$ 32,469
PharmaCann
Variable Interest Entity [Line Items]
Ownership interest				5.80%	5.90%				5.80%	5.90%			6.40%
PharmaCann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	473,787
Cannasoul Lab Services Ltd. \| Variable Interest Entity, Not Primary Beneficiary \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Variable Interest Entity [Line Items]
Collaborative arrangement, percentage of profits to be received								70.00%				70.00%
Collaborative arrangement, profits to be received, maximum percentage of amounts advanced								150.00%				150.00%
Collaborative arrangement, percentage of profits to be received, triggering event, subsequent to maximum percentage of amounts advanced being met								50.00%				50.00%
Cannasoul Lab Services Ltd. \| Variable Interest Entity, Not Primary Beneficiary \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Cannasoul Collaboration Loan \| Loans Receivable
Variable Interest Entity [Line Items]
Collaboration agreement, amount of advances								$ 2,664				₪ 8,297
Collaborative arrangement, term of agreement								2 years
Interest rate								3.50%				3.50%
Cronos GrowCo
Variable Interest Entity [Line Items]
Ownership interest				50.00%				50.00%	50.00%			50.00%
PharmaCann
Variable Interest Entity [Line Items]
Impairment charges		$ 12,916	$ 12,734	$ 23,350	$ 21,182	$ 28,972	$ 11,238	$ 25,650	$ 23,350
PharmaCann \| LivWell Holdings, Inc.
Variable Interest Entity [Line Items]
Merger agreement, threshold ownership percentage														6.00%
Vitura
Variable Interest Entity [Line Items]
Impairment charges								0	0
Loss on revaluation of other investments								6,206	12,096
Other investments				$ 9,601				$ 2,813	$ 9,601
Vitura \| Subsequent Event
Variable Interest Entity [Line Items]
Shares, issued (in shares) \| shares											74,814,757
Ownership interest											8.40%

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 41,080	$ (73,963)	$ (168,734)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) before Income Taxes

For financial reporting purposes, income (loss) from continuing operations before income taxes includes the following components:


	Year ended December 31,
	2024		2023		2022
Income (loss) before income taxes	$	36,586	$	(73,669)	$	(121,003)

Schedule of Expense for Income Taxes

Income tax expense (benefit) consists of the following components:


	Year Ended December 31,
	2024		2023		2022
Current	$	(3,170)	$	(3,375)	$	34,416
Deferred	(266)		145		(241)
Total	$	(3,436)	$	(3,230)	$	34,175

Schedule of Effective Income Tax Rate Reconciliation

Reconciliation of the expected income tax to the effective tax rate in continuing operations is as follows:


	Year ended December 31,
	2024			2023				2022
Income (loss) before income taxes	$	36,586		$	(73,669)		$	$	(121,003)
Effective income tax rate	26.5		%	26.5		%		26.5		%
Expected income tax expense (benefit)	$	9,695		$	(19,522)			$	(32,066)

Non-taxable income (loss)	(11,138)			1,077				(2,140)
Non-deductible share-based compensation	143			525				1,198
Non-deductible expenses	741			459				836
Non-deductible transaction costs	(14)			351				1,625
Effect of provincial tax rate difference	(66)			(9)				(15)
Effect of tax rates outside of Canada	755			816				1,848
Effect of change in tax rates	11,533			4,601				11,041
Fair value gain (loss) on financial liabilities	(15)			23				(3,726)
Changes in valuation allowance	(19,367)			7,930				(10,466)
Capital gain on financial liabilities	—			106				66,193
Additional taxable income	3,746			—				—
Other	551			413				(153)
Income tax expense (benefit), net	$	(3,436)		$	(3,230)			$	34,175

Schedule of Deferred Tax Assets and Liabilities

The following table summarizes the significant components of the Company’s deferred tax assets and liabilities:


	As of December 31,
	2024		2023
Deferred tax assets:
Tax loss carryforwards	$	96,349	$	111,516
Interest expense carryforwards	2,814		2,688


Finance lease obligation	306		519
Plant and equipment	32,130		36,697
Investment	28,778		19,745
Intangible assets	36,428		37,203
Inventory	419		556
Reserve	1,282		2,430
Unrealized foreign exchange	—		275
R&D investment tax credits	1,104		567
Other	3,245		4,271
Total deferred tax assets	202,855		216,467
Less valuation allowance	(200,284)		(216,241)
Net deferred tax assets	2,571		226
Deferred tax liabilities:

Plant and equipment	(1,635)		—
Intangible assets	(1,929)		—


Right-of-use assets	—		(181)

Total deferred tax liabilities	(3,564)		(181)
Net deferred tax asset (liability)	$	(993)	$	45

Schedule of Income Tax Examinations


Jurisdiction						Open Years
Canada						2020 - 2024
United States						2021 - 2024
Israel						2021 - 2024

Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

The following table summarizes the total share-based compensation associated with the Company’s stock options and RSUs:


	Year ended December 31,
	2024		2023		2022
Stock options	$	134	$	1,175	$	6,778
RSUs	8,566		7,581		7,633
Liability-classified awards(i)	—		—		597
Total share-based compensation	$	8,700	$	8,756	$	15,008

Schedule of the Changes in Options

The following is a summary of the changes in options:


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Issuance of options	—		—

Cancellation, forfeiture and expiry of options	19.05		(1,385,937)
Balance as of December 31, 2024	$	5.63	717,264	3.65
Exercisable as of December 31, 2024	$	6.29	554,361	3.23


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of December 31, 2022	$	10.57	5,350,600	0.73
Issuance of options	2.96		188,317

Cancellation, forfeiture and expiry of options	7.75		(3,435,716)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Exercisable as of December 31, 2023	$	15.89	1,864,732	1.29

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.

The following table summarizes stock options outstanding:


	Options outstanding as of December 31,
	2024	2023	2022
2020 Omnibus Plan	702,264	702,264	2,788,947
2018 Stock Option Plan	15,000	1,400,937	1,422,069
2015 Stock Option Plan	—	—	1,139,584
Total stock options outstanding	717,264	2,103,201	5,350,600

Schedule Fair Value of Options Issued

The fair value of the options issued during 2023 was determined using the Black-Scholes option pricing model, using the following inputs:


									2023
Share price at grant date (per share)									C$2.96
Exercise price (per option)									C$2.96
Risk-free interest rate(i)									3.22%
Expected life of options (in years)(i)									7
Expected annualized volatility(i)									73%
Expected dividend yield									—
Weighted average Black-Scholes value at grant date (per option)									C$2.07
Forfeiture rate									—

Schedule of Restricted Share Units Activity

The following is a summary of the changes in RSUs:


	Weighted average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2023	$	3.77	7,381,541
Granted(i)	2.92		2,987,147
Vested and issued	3.49		(1,726,230)
Cancellation and forfeitures	3.18		(260,245)
Balance as of December 31, 2024	$	3.50	8,382,213


	Weighted average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2022	$	4.63	5,725,470
Granted(i)	2.64		3,292,586
Vested and issued	5.00		(1,041,097)
Cancellation and forfeitures	3.60		(595,418)
Balance as of December 31, 2023	$	3.77	7,381,541

(ii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

Schedule of Changes in Warrants and DSUs

The following is a summary of the changes in DSUs:


	Financial liability		Number of DSUs
Balance as of December 31, 2023	$	1,092	521,679
Granting and vesting of DSUs	450		193,965
Liabilities settled	(359)		(155,383)
Gain on revaluation	(54)		—
Balance as of December 31, 2024	$	1,129	560,261


	Financial liability		Number of DSUs
Balance as of December 31, 2022	$	674	265,732
Granting and vesting of DSUs	450		255,947

Loss on revaluation	(32)		—
Balance as of December 31, 2023	$	1,092	521,679

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2024	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	Davidson & Company LLP	KPMG LLP
Auditor Location	Vancouver, BC, Canada	Vaughan, Ontario, Canada
Auditor Firm ID	731	85

Business Combination - Schedule of Fair Values Of Identifiable Assets Acquired And Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jul. 01, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 63,453		$ 1,057
Cronos GrowCo
Business Acquisition [Line Items]
Cash	5,993
Accounts receivable	2,437
Inventory	15,754	$ 15,754
Prepaids and other current assets	795
Intangible assets	8,008
Goodwill	65,269
Property, plant and equipment	87,630	$ 87,630
Accounts payable	(2,913)
Accrued liabilities	(2,757)
Deferred income tax liability	(1,337)
Total purchase price	$ 178,879

Share-based Compensation - Schedule of the Changes in Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 14.50	$ 10.57
Issuance of options (in dollars per share)	0	2.96
Cancellation, forfeiture and expiry of options (in dollars per share)	19.05	7.75
Balance at end of period (in dollars per share)	5.63	14.50	$ 10.57
Exercisable (in dollars per share)	$ 6.29	$ 15.89
Number of options
Balance at beginning of period (in shares)	2,103,201	5,350,600
Issuance of options (in shares)	0	188,317
Cancellation of options (in shares)	(1,385,937)	(3,435,716)
Balance at end of period (in shares)	717,264	2,103,201	5,350,600
Exercisable (in shares)	554,361	1,864,732
Weighted average remaining contractual term (years)
Outstanding	3 years 7 months 24 days	1 year 10 months 2 days	8 months 23 days
Exercisable	3 years 2 months 23 days	1 year 3 months 14 days

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Tax loss carryforwards	$ 96,349	$ 111,516
Interest expense carryforwards	2,814	2,688
Finance lease obligation	306	519
Plant and equipment	32,130	36,697
Investment	28,778	19,745
Intangible assets	36,428	37,203
Inventory	419	556
Reserve	1,282	2,430
Unrealized foreign exchange	0	275
R&D investment tax credits	1,104	567
Other	3,245	4,271
Total deferred tax assets	202,855	216,467
Less valuation allowance	(200,284)	(216,241)
Net deferred tax assets	2,571	226
Deferred tax liabilities:
Plant and equipment	(1,635)	0
Intangible assets	(1,929)	0
Right-of-use assets	0	(181)
Total deferred tax liabilities	(3,564)	(181)
Net deferred tax liability	$ (993)
Net deferred tax assets		$ 45

Income (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Basic income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$ 41,080	$ (69,849)	$ (155,178)
Weighted-average number of common shares outstanding for computation for basic income (loss) per share (in shares)	382,058,056	380,964,739	376,961,797
Basic income (loss) from continuing operations per share (in dollars per share)	$ 0.11	$ (0.18)	$ (0.41)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ 0	$ (4,114)	$ (13,556)
Basic loss from discontinued operations per share (in dollars per share)	$ 0	$ (0.01)	$ (0.04)
Diluted income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$ 41,080	$ (69,849)	$ (155,178)
Weighted-average number of common shares outstanding for computation for basic income (loss) per share (in shares)	382,058,056	380,964,739	376,961,797
Dilutive effect of RSUs (in shares)	3,243,564	0	0
Dilutive effect of Top-up Rights – market price (in shares)	255,382	0	0
Weighted-average number of common shares for computation of diluted income (loss) from continuing and discontinuing operations per share (in shares)	385,557,002	380,964,739	376,961,797
Diluted income (loss) from continuing operations per share (in dollars per share)	$ 0.11	$ (0.18)	$ (0.41)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ 0	$ (4,114)	$ (13,556)
Diluted loss from discontinued operations per share (in dollars per share)	$ 0	$ (0.01)	$ (0.04)
Total anti-dilutive securities (in shares)	17,070,836	25,426,119	112,612,579

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 11,789	$ 13,066
Increase (decrease)	(10,772)	(1,528)
Foreign exchange effect	(394)	251
Ending balance	623	11,789	$ 13,066
Financing receivable, credit loss, expense, including transferred into investment	1,032	(1,528)
Gain on revaluation of loan receivable	11,804	0	0
Cronos GrowCo(i)
Allowance for Loan and Lease Losses [Roll Forward]
Gain on revaluation of loan receivable	11,804
GrowCo Credit Facility(ii) \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	11,176	12,455
Increase (decrease)	(10,794)	(1,542)
Foreign exchange effect	(382)	263
Ending balance	0	11,176	12,455
Mucci Promissory Note \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	89	89
Increase (decrease)	6	(2)
Foreign exchange effect	(7)	2
Ending balance	88	89	89
Cannasoul Collaboration Loan \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	524	522
Increase (decrease)	16	16
Foreign exchange effect	(5)	(14)
Ending balance	$ 535	$ 524	$ 522

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Goodwill and Intangible Assets, net

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, net

(a)Goodwill

Goodwill is comprised of the following items:


	As of December 31, 2024
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	976	$	—	$	976
Cronos GrowCo	62,477		—		62,477
	$	63,453	$	—	$	63,453


	As of December 31, 2023
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,057	$	—	$	1,057
	$	1,057	$	—	$	1,057

(b)Intangible assets, net

In the fourth quarter of 2023, the Company determined that it had no current plans to utilize the intellectual property associated with one of its exclusive licenses with Ginkgo and, therefore, recognized $3,366 in impairment charges on the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2023.

In the third quarter of 2024, the Company determined that it was no longer utilizing and had no current plans to utilize the intellectual property associated with its other exclusive licenses with Ginkgo. As a result, the remaining net book value of $14,258 was impaired and recorded to impairment loss on long-lived assets on the consolidated statements of income (loss) and comprehensive income (loss) in the year ended December 31, 2024.

Intangible assets, net are comprised of the following items:


		As of December 31, 2024
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,988		$	(4,646)		$	(72)		$	2,270
Health Canada licenses		7,810			(1,673)			(6,137)			—
Ginkgo exclusive licenses		26,139			(5,329)			(20,810)			—
Israeli codes(i)		281			(76)			—			205
Know-how(ii)		7,665			(383)			—			7,282
Total definite-lived intangible assets		48,883			(12,107)			(27,019)			9,757
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	113,025		$	(12,107)		$	(89,661)		$	11,257


		December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

The estimated future amortization of definite-lived intangible assets is as follows:


	As of December 31, 2024
2025	$	2,125
2026	1,479
2027	974
2028	800
2029	795
Thereafter	3,584
	$	9,757

Impairment of Intangible Assets

Accumulated impairment charges on intangible assets, net consist of:


	As of December 31, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2024
Software	$	(78)	$	—	$	6	$	(72)
Health Canada licenses	(6,650)		—		513		(6,137)
Ginkgo exclusive licenses	(7,968)		(14,258)		1,416		(20,810)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(77,338)	$	(14,258)	$	1,935	$	(89,661)


	As of December 31, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of December 31, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)

Share-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 8,700	$ 8,756	$ 15,008
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	134	1,175	6,778
Restricted Stock Units (RSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	8,566	$ 7,581	7,633
Liability Classified Awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 0		$ 597

Leases - Schedule of Lease Cost and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lease cost
Operating lease cost	$ 613	$ 685	$ 1,107
Short-term lease cost	0	0	0
Total lease cost	613	685	1,107
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	1,137	1,124	1,441
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	$ 566	$ 0	$ 0
Weighted-average remaining lease term (years) – operating leases	3 years 7 months 6 days	3 years 7 months 6 days	4 years 3 months 18 days
Weighted-average discount rate – operating leases	7.71%	7.62%	7.39%

Inventory, net

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

Inventory, net

Inventory, net is comprised of the following items:


	As of December 31,
	2024		2023
Raw materials	$	5,400	$	4,795
Work-in-progress	14,350		10,593
Finished goods	13,248		14,819
Supplies and consumables	151		288
Total	$	33,149	$	30,495

As a result of the Cronos GrowCo Transaction, the Company recorded a step-up to Cronos GrowCo’s existing inventory of $5,605 to bring the inventory balance acquired by the Company to its fair value. For the year December 31, 2024, the Company recognized $5,284 of this inventory step-up into cost of sales on the consolidated statements of income (loss) and comprehensive income (loss). See Note 2 “Business Combination” for more information.

Related Party Transactions - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Mar. 08, 2019
Related Party Transaction [Line Items]
Accounts payable	$ 16,973,000	$ 12,130,000
Consulting Arrangement
Related Party Transaction [Line Items]
Related party transaction amount	434,000
Related Party
Related Party Transaction [Line Items]
Carrying value of held for sale assets sold		332,000
Proceeds from sale of assets		761,000
Gain on sale of assets		436,000
Related Party \| Consulting Services
Related Party Transaction [Line Items]
Accounts payable	0	0
Related Party \| Cannabis Purchases
Related Party Transaction [Line Items]
Accounts payable		2,267,000
Purchases	16,952,000	21,335,000	$ 18,144,000
Related Party \| Cannabis Germplasm Supply Agreement
Related Party Transaction [Line Items]
Related party transaction amount		1,114,000
Related Party \| Manufacturing Services
Related Party Transaction [Line Items]
Accounts payable	149,000	11,000
Purchases	1,746,000	42,000
Related Party \| Consulting Arrangement
Related Party Transaction [Line Items]
Accounts payable	0
Immediate Family Member of Management or Principal Owner \| Manufacturing Services
Related Party Transaction [Line Items]
Accounts payable	0	28,000
Purchases	$ 0	$ 2,310,000
Cronos Group, Inc. \| Altria Group, Inc.
Related Party Transaction [Line Items]
Ownership interest	40.90%			45.00%
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest	50.00%	50.00%
Cronos GrowCo \| Consulting Arrangement
Related Party Transaction [Line Items]
Ownership interest	50.00%

Income (Loss) per Share

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Income (Loss) per Share

Basic and diluted earnings (loss) per share from continued and discontinued operations are calculated as follows:


	Year ended December 31,
	2024		2023		2022
Basic income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$	41,080	$	(69,849)	$	(155,178)
Weighted-average number of common shares outstanding for computation for basic income (loss) per share	382,058,056		380,964,739		376,961,797
Basic income (loss) from continuing operations per share	$	0.11	$	(0.18)	$	(0.41)


Loss from discontinued operations attributable to the shareholders of Cronos Group	$	—	$	(4,114)	$	(13,556)
Weighted-average number of common shares outstanding for computation of basic loss from discontinued operations per share	382,058,056		380,964,739		376,961,797
Basic loss from discontinued operations per share	$	—	$	(0.01)	$	(0.04)


Diluted income (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$	41,080	$	(69,849)	$	(155,178)



Weighted-average number of common shares outstanding used in the computation of basic income (loss) per share	382,058,056		380,964,739		376,961,797


Dilutive effect of RSUs	3,243,564		—		—

Dilutive effect of Top-up Rights – market price	255,382		—		—
Weighted-average number of common shares for computation of diluted income (loss) from continuing operations per share(i)	385,557,002		380,964,739		376,961,797
Diluted income (loss) from continuing operations per share	$	0.11	$	(0.18)	$	(0.41)

Loss from discontinued operations attributable to the shareholders of Cronos Group	$	—	$	(4,114)	$	(13,556)
Weighted-average number of common shares for computation of diluted loss from discontinued operations per share	382,058,056		380,964,739		376,961,797
Diluted loss from discontinued operations per share	$	0.00	$	(0.01)	$	(0.04)

Total securities of 17,070,836, 25,426,119 and 112,612,579 were not included in the computation of diluted shares outstanding for the years ended December 31, 2024, 2023 and 2022, respectively, because the effect would be anti-dilutive.

Inventory, net (Tables)

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory, net is comprised of the following items:


	As of December 31,
	2024		2023
Raw materials	$	5,400	$	4,795
Work-in-progress	14,350		10,593
Finished goods	13,248		14,819
Supplies and consumables	151		288
Total	$	33,149	$	30,495

Income Taxes - Schedule of Income (Loss) before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 36,586	$ (73,669)	$ (121,003)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Discontinued Operations - Schedule of Revenue by Major Product Category (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,029	$ 5,155
Cannabis extracts
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,029	$ 5,155

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Intangible Assets Amortization Methods and Rates (Details)	Dec. 31, 2024
Software
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years
Know-How
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Financial Instruments - Schedule of Fair Value of Assets on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 2,813	$ 35,251	$ 70,993
Derivative liabilities	40	102
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	858,805	669,291
Short-term investments		192,237
Other investments	2,813	9,601
Derivative liabilities	40	102
Level 1 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	858,805	669,291
Short-term investments		192,237
Other investments	2,813	9,601
Derivative liabilities	0	0
Level 2 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments		0
Other investments	0	0
Derivative liabilities	0	0
Level 3 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments		0
Other investments	0	0
Derivative liabilities	$ 40	$ 102

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-103

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1

+ Details

Segment Information - Schedule of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net income		$ 40,022	$ (74,553)	$ (168,734)
Interest income, net		(52,019)	(51,235)	(22,514)
Income tax benefit		(3,436)	(3,230)	34,175
Depreciation and amortization		9,336	8,110	13,122
Share of income from equity method investments		(2,365)	(1,583)	(3,114)
Impairment loss on long-lived assets		16,350	3,366	3,493
Revaluation gain on loan receivable		(11,804)	0	0
Gain on revaluation of equity method investment		(32,469)	0	0
Gain (loss) on revaluation of derivative liabilities		(49)	85	(14,060)
Gain (loss) on revaluation of financial instruments		6,248	12,042	(14,739)
Impairment loss on other investments		25,650	23,350	61,392
Foreign currency transaction (gain) loss		(57,859)	7,324	2,286
Loss on held-for-sale assets		11,202	0	0
Other, net		350	(1,114)	324
Share-based compensation		8,700	8,756	15,008
Inventory write-down		707	805	0
Inventory step-up recorded to cost of sales		5,284	0	0
Realignment
Segment Reporting Information [Line Items]
Loss on held-for-sale assets	$ 345	10,422
Inventory write-down		805
Impairment loss on long-lived assets		1,631
Ginkgo exclusive licenses
Segment Reporting Information [Line Items]
impairment loss on long-lived assets		14,258	3,366	0
Continuing and Discontinued Operations
Segment Reporting Information [Line Items]
Net income		40,022	(74,553)	(168,734)
Interest income, net		(52,019)	(51,245)	(22,537)
Income tax benefit		(3,436)	(3,230)	34,175
Depreciation and amortization		9,336	8,110	13,122
EBITDA		(6,097)	(120,918)	(143,974)
Share of income from equity method investments		(2,365)	(1,583)	(3,114)
Impairment loss on long-lived assets		16,350	3,571	3,493
Revaluation gain on loan receivable		(11,804)
Gain on revaluation of equity method investment		(32,469)
Gain (loss) on revaluation of derivative liabilities		(49)	85	(14,060)
Gain (loss) on revaluation of financial instruments		6,248	12,042	(14,739)
Impairment loss on other investments		25,650	23,350	61,392
Foreign currency transaction (gain) loss		(57,859)	7,324	2,286
Transaction costs		701
Loss on held-for-sale assets		11,202
Other, net		350	(996)	493
Restructuring costs		630	2,047	5,333
Share-based compensation		8,700	8,769	15,115
Financial statement review costs		(1)	919	7,167
Inventory write-down			1,644
Inventory step-up recorded to cost of sales		5,284
Israel Ministry of Economy and Industry dumping inquiry expense		587
Adjusted EBITDA		(34,942)	(63,746)	(80,608)
Continuing Operations
Segment Reporting Information [Line Items]
Net income		40,022	(70,439)	(155,178)
Interest income, net		(52,019)	(51,235)	(22,514)
Income tax benefit		(3,436)	(3,230)	34,175
Depreciation and amortization		9,336	7,866	11,924
EBITDA		(6,097)	(117,038)	(131,593)
Share of income from equity method investments		(2,365)	(1,583)	(3,114)
Impairment loss on long-lived assets		16,350	3,366	3,493
Revaluation gain on loan receivable		(11,804)
Gain on revaluation of equity method investment		(32,469)
Gain (loss) on revaluation of derivative liabilities		(49)	85	(14,060)
Gain (loss) on revaluation of financial instruments		6,248	12,042	(14,739)
Impairment loss on other investments		25,650	23,350	61,392
Foreign currency transaction (gain) loss		(57,859)	7,324	2,286
Transaction costs		701
Loss on held-for-sale assets		11,202
Other, net		350	(1,114)	324
Restructuring costs		630	1,524	3,545
Share-based compensation		8,700	8,756	15,008
Financial statement review costs		(1)	919	7,167
Inventory write-down			805
Inventory step-up recorded to cost of sales		5,284
Israel Ministry of Economy and Industry dumping inquiry expense		587
Adjusted EBITDA		(34,942)	(61,564)	(70,291)
Discontinued Operations
Segment Reporting Information [Line Items]
Net income		0	(4,114)	(13,556)
Interest income, net		0	(10)	(23)
Income tax benefit		0	0	0
Depreciation and amortization		0	244	1,198
EBITDA		0	(3,880)	(12,381)
Share of income from equity method investments		0	0	0
Impairment loss on long-lived assets		0	205	0
Revaluation gain on loan receivable		0
Gain on revaluation of equity method investment		0
Gain (loss) on revaluation of derivative liabilities		0	0	0
Gain (loss) on revaluation of financial instruments		0	0	0
Impairment loss on other investments		0	0	0
Foreign currency transaction (gain) loss		0	0	0
Transaction costs		0
Loss on held-for-sale assets		0
Other, net		0	118	169
Restructuring costs		0	523	1,788
Share-based compensation		0	13	107
Financial statement review costs		0	0	0
Inventory write-down			839
Inventory step-up recorded to cost of sales		0
Israel Ministry of Economy and Industry dumping inquiry expense		0
Adjusted EBITDA		$ 0	$ (2,182)	$ (10,317)

Financial Instruments - Interest Rate Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Effect of 10% change in interest rate on interest income, net	$ 5,200
Interest income, net	$ 52,019	$ 51,235	$ 22,514

Business Combination (Tables)

12 Months Ended

Dec. 31, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of Fair Value of Net Assets Acquired

During the fourth quarter of 2024, the Company completed the allocation of the purchase price to the assets acquired and liabilities assumed. Based on the final allocation, goodwill and intangible assets increased $28,848 and $8,008, respectively, and property, plant and equipment, inventory and deferred tax liability decreased $31,970, $15,287 and $10,401, respectively, from the preliminary amount reported in the Company’s condensed consolidated financial statements as of September 30, 2024. These changes in the allocation of the purchase price did not have a material impact on previously reported earnings. The final allocation of the purchase price to the fair values of the assets acquired and liabilities assumed was:


Cash	$	5,993
Accounts receivable	2,437
Inventory	15,754
Prepaids and other current assets	795
Intangible assets	8,008
Goodwill	65,269
Property, plant and equipment	87,630
Accounts payable	(2,913)
Accrued liabilities	(2,757)
Deferred income tax liability	(1,337)
Total purchase price	$	178,879

The following table presents details of the property, plant and equipment acquired by major category:


	Fair value at date of Cronos GrowCo Transaction
Land	$	4,557
Building and leasehold improvements	49,356
Machinery and equipment	21,603
Furniture and fixtures	580
Construction in progress	11,534
Total	$	87,630

The following table presents details of the intangible assets acquired:


	Fair value at date of acquisition		Amortization period (in years)
Know-how	$	8,008	10
Total	$	8,008

Schedule of Supplemental Pro Forma Results

The following table presents unaudited supplemental pro forma results for the year ended December, 31 2024 and 2023, respectively, as if the Cronos GrowCo Transaction had occurred as of January 1, 2023. The unaudited pro forma information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the business combination had taken place at such time. The unaudited pro forma results presented below include adjustments such as amortization of inventory step-up, amortization charges for acquired intangible assets, depreciation adjustments for property, plant and equipment that has been revalued, adjustment of interest expense and interest income resulting from the effective settlement of pre-existing debt financing in connection with the Cronos GrowCo Transaction and adjustments for certain business combination-related charges.


	Year ended December 31,
		2024		2023
Net revenue		$	125,089	$	106,700
Gross profit		35,906		18,500
Operating expenses		103,031		101,995
Other income		66,202		49,441
Net income (loss) attributable to Cronos Group		13,582		(44,256)

Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Line Items]
Cost	$ 63,453	$ 1,057
Accumulated impairment charges	0	0
Net	63,453	1,057
Peace Naturals
Goodwill [Line Items]
Cost	976	1,057
Accumulated impairment charges	0	0
Net	976	$ 1,057
Cronos GrowCo
Goodwill [Line Items]
Cost	62,477
Accumulated impairment charges	0
Net	$ 62,477

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Commitments and Contingencies - R&D Commitments (Details) - USD ($) $ in Thousands			12 Months Ended
	Feb. 18, 2019	Sep. 04, 2018	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jul. 17, 2018
Ginkgo \| Share capital and additional paid-in capital
Long-term Purchase Commitment [Line Items]
Share issuance pursuant to research and development milestone (in shares)			0	0	4,157,888	2,934,980
Ginkgo \| Research and Development Arrangement
Long-term Purchase Commitment [Line Items]
Common shares issuable (up to) (in shares)		14,674,903
Common shares issuable, value assigned							$ 100,000
Payments subject to milestones		$ 22,000
Altria Ventures \| Consulting Services Arrangement
Long-term Purchase Commitment [Line Items]
Monthly fee, percentage of direct and indirect service costs	105.00%

Business Combination

12 Months Ended

Dec. 31, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Business Combinations

Business Combination

Cronos GrowCo was formed under the Canada Business Corporations Act on June 14, 2018, with the objective of cultivating and commercializing cannabis and cannabis products. Cronos GrowCo is licensed to sell certain cannabis products to other license holders in the wholesale channel, as well as to provincial cannabis control authorities. It is also licensed to export dried flower to Israel.

As described in Note 1 “Background, Basis of Presentation, and Summary of Significant Accounting Policies”, in the third quarter of 2024, the Company obtained majority control of the board of directors of Cronos GrowCo, which qualified as a business combination under ASC 805. In connection with the Cronos GrowCo Transaction, the Company provided an approximately $51,000 secured non-revolving credit facility to Cronos GrowCo to fund the expansion of Cronos GrowCo’s cultivation and processing facilities (such area, the “Phase 2 Expansion Area”), and the Company entered into a new supply agreement (the “Cronos GrowCo Supply Agreement”) with Cronos GrowCo. Pursuant to the Cronos GrowCo Supply Agreement, prior to the commencement of sales from the Phase 2

Expansion Area, the Company and its controlled affiliates (other than Cronos GrowCo) have the right, but not the obligation, to purchase an aggregate total quantity of 80% of Cronos GrowCo’s production. Thereafter, the Company and its controlled affiliates (other than Cronos GrowCo) will have the right, but not the obligation, to purchase 70% of Cronos GrowCo’s forecasted production capacity over a given period and 70% of Cronos GrowCo’s actual production in a given month. Cronos GrowCo’s production is intended to support the majority of the Company’s current and future biomass supply requirements.

As there was no cash consideration paid, the Cronos GrowCo Transaction has been valued with reference to the fair value of our existing equity method investment of $53,542, as well as the effective settlement of various preexisting relationships between the Company and Cronos GrowCo. These preexisting relationships are now classified as intercompany transactions and eliminated upon consolidation. For the year ended December 31, 2024, we recorded a gain of $32,469 on the consolidated statements of net income (loss) and comprehensive income (loss) from remeasuring our equity method investment in Cronos GrowCo. We also recorded $11,804 to gain on revaluation of loan receivable on the consolidated statements of net income (loss) and comprehensive income (loss) for the year ended December 31, 2024, from remeasuring our outstanding loans receivable with Cronos GrowCo. Additionally, the consideration also included the effective settlement of various preexisting trade receivables and payables and other related accounts that are now classified as intercompany transactions and eliminated upon consolidation. The effective settlement of the preexisting trade receivables, payables, and related accounts did not result in the recognition of any gain or loss on settlement. As of the date of the Cronos GrowCo Transaction, the fair value of the non-controlling interest in Cronos GrowCo was $53,542. The Company used the income approach to estimate both the fair value of the Company’s equity method investment in Cronos GrowCo and the fair value of the non-controlling interest in Cronos GrowCo. Under the income approach, significant assumptions used in the discounted cash flow method that required the use of judgment were the discount rate, growth rates and cash flow projections. The Company used the income approach to estimate the fair value of the Company’s loan receivable with Cronos GrowCo. Under the income approach, significant assumptions used that required the use of judgment were the credit spread and interest rate volatility.


Cash	$	5,993
Accounts receivable	2,437
Inventory	15,754
Prepaids and other current assets	795
Intangible assets	8,008
Goodwill	65,269
Property, plant and equipment	87,630
Accounts payable	(2,913)
Accrued liabilities	(2,757)
Deferred income tax liability	(1,337)
Total purchase price	$	178,879

The inventory acquired in the Cronos GrowCo Transaction of $15,754 includes a step-up to fair value of $5,605. For the year ended December, 31 2024, the Company recognized $5,284 of this inventory step-up into cost of sales on the consolidated statements of income (loss) and comprehensive income (loss).

The following table presents details of the property, plant and equipment acquired by major category:


	Fair value at date of Cronos GrowCo Transaction
Land	$	4,557
Building and leasehold improvements	49,356
Machinery and equipment	21,603
Furniture and fixtures	580
Construction in progress	11,534
Total	$	87,630

The following table presents details of the intangible assets acquired:


	Fair value at date of acquisition		Amortization period (in years)
Know-how	$	8,008	10
Total	$	8,008

The Company’s results of operations for the year ended December, 31 2024, included six months of the operating results of Cronos GrowCo, which was comprised of revenue of $6,374 and loss before income taxes of $802. Business combination-related costs of $701 were incurred in relation to the Cronos GrowCo Transaction for the year ended December, 31 2024, and were reported in general and administrative expenses on the consolidated statements of net income (loss) and comprehensive income (loss).

As a result of the Cronos GrowCo Transaction, the Company recorded goodwill of $65,269, none of which is deductible for income tax purposes. The goodwill acquired was primarily attributable to the ability to realize synergies, bolster Cronos’ supply capabilities and support future growth opportunities from the expansion of Cronos GrowCo’s cultivation and processing facilities.


	Year ended December 31,
		2024		2023
Net revenue		$	125,089	$	106,700
Gross profit		35,906		18,500
Operating expenses		103,031		101,995
Other income		66,202		49,441
Net income (loss) attributable to Cronos Group		13,582		(44,256)

Material nonrecurring pro forma adjustments directly attributable to the Cronos GrowCo Transactions include the following:

•Acquired inventory fair value step-up of $5,605 is assumed to be recorded at January 1, 2023. As such, historical amortization of the acquired inventory step-up of $5,284 recognized in the historical six-month period ended December 31, 2024 was removed from pro forma net income for the year ended December, 31 2024. The entire inventory fair value step-up of $5,605 was recognized as an incremental product cost in the year ended December 31, 2023.

•Pre-business combination revenues for sales from Cronos GrowCo to the Company of $21,145 were adjusted out for the year ended December 31, 2023, and $14,776 of pre-business combination revenues were adjusted out for the year ended December, 31 2024, as these amounts would have been eliminated in consolidation. Company pre-business combination cost of sales of $17,988 were adjusted out for the year ended December 31, 2023, and $11,386 of pre-business combination cost of sales were adjusted out for the year ended December 31, 2024, as these amounts would have been eliminated in consolidation.

•The gain on the revaluation of the equity method investment and loan receivable relating to the Cronos GrowCo Transaction of $32,469 and $11,804, respectively, were adjusted out for the year ended December, 31 2024 and added into the year ended December 31, 2023 as this revaluation is assumed to have occurred on January 1, 2023.

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Derivative Instruments [Roll Forward]
Beginning balance	$ 102	$ 15
Loss (gain) on revaluation	(49)	85
Foreign exchange effect	(13)	2
Ending balance	40	102
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	102	0
Loss (gain) on revaluation	(49)	100
Foreign exchange effect	(13)	2
Ending balance	40	102
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	0	15
Loss (gain) on revaluation	0	(15)
Foreign exchange effect	0	0
Ending balance	$ 0	$ 0

Consolidated Balance Sheet (Parenthetical) - shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	382,530,780	381,298,853
Common stock, shares outstanding (in shares)	382,530,780	381,298,853

Derivative Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Reconciliation of Carrying Amounts

Reconciliations of the carrying amounts of the derivative liability are presented below:


	As of December 31, 2023		Loss (gain) on revaluation		Foreign exchange effect		As of December 31, 2024

Pre-emptive Rights	102		(49)		(13)		40
Top-up Rights	—		—		—		—
	$	102	$	(49)	$	(13)	$	40


	As of December 31, 2022		Gain on revaluation		Foreign exchange effect		As of December 31, 2023

Pre-emptive Rights	—		100		2		102
Top-up Rights	15		(15)		—		—
	$	15	$	85	$	2	$	102

Schedule of Fair Values of Derivative Liabilities

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:


	As of December 31, 2024
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.89	$2.89
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	2.89%	3.01%
Weighted average expected life (in years)(ii)	2.00	0.75
Expected annualized volatility(iii)	49%	48%
Expected dividend yield	—%	—%


	As of December 31, 2023
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.77	$2.77
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	3.99%	4.76%
Weighted average expected life (in years)(ii)	1.75	0.60
Expected annualized volatility(iii)	60%	58%
Expected dividend yield	—%	—%

up Rights are linked. As of December 31, 2024 and December 31, 2023, the expected life uses a range of approximately 0.75 years to 2.00 years and 0.50 years to 1.75 years, respectively.

(iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Goodwill and Intangible Assets, net (Tables)

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill is comprised of the following items:


	As of December 31, 2024
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	976	$	—	$	976
Cronos GrowCo	62,477		—		62,477
	$	63,453	$	—	$	63,453


	As of December 31, 2023
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,057	$	—	$	1,057
	$	1,057	$	—	$	1,057

Schedule of Finite-Lived Intangible Assets

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities
Know-how(ii)	Straight-line	10 years

(ii) Know-how was acquired as part of the Cronos GrowCo Transaction. See Note 2 “Business Combination” for further information.

Intangible assets, net are comprised of the following items:


		As of December 31, 2024
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,988		$	(4,646)		$	(72)		$	2,270
Health Canada licenses		7,810			(1,673)			(6,137)			—
Ginkgo exclusive licenses		26,139			(5,329)			(20,810)			—
Israeli codes(i)		281			(76)			—			205
Know-how(ii)		7,665			(383)			—			7,282
Total definite-lived intangible assets		48,883			(12,107)			(27,019)			9,757
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	113,025		$	(12,107)		$	(89,661)		$	11,257


		December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Accumulated impairment charges on intangible assets, net consist of:


	As of December 31, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2024
Software	$	(78)	$	—	$	6	$	(72)
Health Canada licenses	(6,650)		—		513		(6,137)
Ginkgo exclusive licenses	(7,968)		(14,258)		1,416		(20,810)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(77,338)	$	(14,258)	$	1,935	$	(89,661)


	As of December 31, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of December 31, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)

Schedule of Indefinite-Lived Intangible Assets

Intangible assets, net are comprised of the following items:


		As of December 31, 2024
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,988		$	(4,646)		$	(72)		$	2,270
Health Canada licenses		7,810			(1,673)			(6,137)			—
Ginkgo exclusive licenses		26,139			(5,329)			(20,810)			—
Israeli codes(i)		281			(76)			—			205
Know-how(ii)		7,665			(383)			—			7,282
Total definite-lived intangible assets		48,883			(12,107)			(27,019)			9,757
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	113,025		$	(12,107)		$	(89,661)		$	11,257


		December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Accumulated impairment charges on intangible assets, net consist of:


	As of December 31, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2024
Software	$	(78)	$	—	$	6	$	(72)
Health Canada licenses	(6,650)		—		513		(6,137)
Ginkgo exclusive licenses	(7,968)		(14,258)		1,416		(20,810)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(77,338)	$	(14,258)	$	1,935	$	(89,661)


	As of December 31, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of December 31, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)

Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets

The estimated future amortization of definite-lived intangible assets is as follows:


	As of December 31, 2024
2025	$	2,125
2026	1,479
2027	974
2028	800
2029	795
Thereafter	3,584
	$	9,757

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Income Taxes - Schedule of Expense for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current	$ (3,170)	$ (3,375)	$ 34,416
Deferred	(266)	145	(241)
Income tax expense (benefit), net	$ (3,436)	$ (3,230)	$ 34,175

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Consolidated Entities (Details)	12 Months Ended
	Dec. 31, 2024
Cronos Growing Company Inc.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	50.00%
Cronos Israel G.S. Cultivations Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	70.00%
Cronos Israel G.S. Manufacturing Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%
Cronos Israel G.S. Store Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%
Cronos Israel G.S. Pharmacy Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%

Share-based Compensation - Stock Options Narrative (Details) - $ / shares		12 Months Ended
	Mar. 29, 2020	Dec. 31, 2024	Dec. 31, 2023	Jun. 25, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of options (in shares)		0	188,317
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)			$ 2.96
Stock options \| 2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Future awards to be granted (in shares)				0
Stock options \| 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	7 years
Stock options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Stock options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Stock options \| Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)			$ 2.07

Loans Receivable, net (Tables)

12 Months Ended

Dec. 31, 2024

Receivables [Abstract]

Schedule of Loan Receivable

Loans receivable, net consists of the following:


	As of December 31,
	2024		2023


GrowCo Credit Facility(i)	$	—	$	5,034
Add: Current portion of Mucci Promissory Note accrued interest	618		507
Total current portion of loans receivable	618		5,541
GrowCo Credit Facility(i)	—		53,638
Mucci Promissory Note	13,464		13,379
Cannasoul Collaboration Loan	1,736		1,771
Add: Long-term portion of accrued interest	326		248
Total long-term portion of loans receivable	15,526		69,036
Total loans receivable(i)	$	16,144	$	74,577

Schedule of Financing Receivable, Allowance for Credit Loss

Expected credit loss allowances on the Company’s long-term financial assets were comprised of the following items:


	As of December 31, 2023		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2024
GrowCo Credit Facility(ii)	$	11,176	$	(10,794)	$	(382)	$	—

Mucci Promissory Note	89		6		(7)		88
Cannasoul Collaboration Loan	524		16		(5)		535
	$	11,789	$	(10,772)	$	(394)	$	623


	As of December 31, 2022		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2023
GrowCo Credit Facility	$	12,455	$	(1,542)	$	263	$	11,176

Mucci Promissory Note	89		(2)		2		89
Cannasoul Collaboration Loan	522		16		(14)		524
	$	13,066	$	(1,528)	$	251	$	11,789

Property, Plant and Equipment, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Property, Plant and Equipment [Line Items]
Aggregate depreciation expense		$ 5,506	$ 3,913	$ 8,667
Impairment loss on long-lived assets		16,350	$ 3,366	$ 3,493
Realignment
Property, Plant and Equipment [Line Items]
Impairment loss on long-lived assets		1,631
Realignment \| Disposal Group, Held-for-Sale, Not Discontinued Operations \| Cronos Fermentation
Property, Plant and Equipment [Line Items]
Current assets of discontinued operations		$ 8,112			$ 19,398
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Impairment loss on long-lived assets	$ 1,507

Share-based Compensation - Schedule of Fair Value of Options Issued (Details) - Stock options	12 Months Ended
	Dec. 31, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)	$ 2.96
Exercise price (per option) (in Canadian dollars per share)	$ 2.96
Risk-free interest rate	3.22%
Expected life of options	7 years
Expected annualized volatility	73.00%
Expected dividend yield	0.00%
Weighted average Black-Scholes value at grant date (per option) (in Canadian dollars per share)	$ 2.07
Forfeiture rate	0.00%

Property, Plant and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

7 to 10 years

Furniture and fixtures

5 years

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2024		2023
Cost
Land		$	6,389	$	2,764
Building and leasehold improvements		192,059		168,498
Machinery and equipment		36,741		21,322
Furniture and fixtures		2,687		3,385
Construction in progress		28,710		3,269
Less: accumulated depreciation		(29,798)		(30,707)
Less: accumulated impairment charges		(103,599)		(109,063)
Property, Plant and Equipment, net		$	133,189	$	59,468

The following table presents details of the property, plant and equipment acquired on July 1, 2024, as a result of the Cronos GrowCo Transaction by major category:


	Fair value at date of Cronos GrowCo Transaction
Land	$	4,557
Building and leasehold improvements	49,356
Machinery and equipment	21,603
Furniture and fixtures	580
Construction in progress	11,534
Total	$	87,630

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Accrued payroll and related expenses	$ 10,324	$ 8,970
Accrued professional fees	1,537	2,525
Accrued taxes	11,831	11,695
Other accrued expenses	7,961	4,546
Total accrued liabilities	$ 31,653	$ 27,736